4 Market Access

Healthcare Market Access: Morocco

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY ...... 5 2 COUNTRY LANDSCAPE...... 7 2.1 Geography ...... 7 2.2 Economic environment...... 8 2.3 Demographics...... 10 2.4 Political structure and environment...... 13 3 HEALTHCARE INFRASTRUCTURE...... 14 3.1.1 Healthcare system...... 16 4 MARKET ACCESS...... 20 4.1 Health insurance system...... 20 4.1.1 AMO: Mandatory health insurance (Assurance Maladie Obligatoire)...... 21 4.1.2 RAMED: Medical assistance scheme (Régime d’Assistance Médicale)...... 24 4.1.3 INAYA: Health insurance for the self-employed...... 25 4.2 Drug prescribing and dispensing practices...... 27 4.3 Comparison of regional regulatory agencies and environment ...... 28 4.3.1 Southern African Development Community (SADC):...... 30 4.3.2 Economic Community of West African States (ECOWAS):...... 30 4.3.3 East African Community (EAC): ...... 30 4.4 Drug approval and reimbursement process in Morocco...... 31 5 CONCLUSION ...... 33 6 APPENDIX...... 34 6.1 Glossary...... 34 6.2 Coverage rates for long-term and costly conditions...... 36 6.3 Essential drug list of Morocco...... 40 6.4 Reimbursement of anti-cancer drugs (in MAD)...... 68 6.5 Bibliography...... 83 6.6 Methodology...... 84 6.6.1 Secondary research...... 84 6.6.2 Data validation...... 84 6.7 Disclaimer...... 84 6.8 Contact us ...... 85

LIST OF TABLES

Table 1: GDP Real growth rate of Morocco...... 8 Table 2: GDP composition (2012 estimates) by sector of origin ...... 8 Table 3: Demographic breakdown of Morocco based on 2014 estimates...... 11 Table 4: Major urban cities and their population based on 2011 estimates...... 11 Table 5: Educational parameters ...... 12 Table 6: Access to safe drinking water and sanitation ...... 14 Table 7: Healthcare indicators of Morocco ...... 16 Table 8: Breakdown of healthcare delivery in public and private sectors...... 17 Table 9: Breakdown of income and major expenditure of CNSS and CNOPS for 2012...... 24 Table 10: Breakdown of income and major expenditure of RAMED for 2012 ...... 25 Table 11: Coverage rates for long-term and costly conditions...... 36 Table 12: Coverage rate of lasting and costly disorders...... 39 Table 13: Essential drug list of Morocco...... 40 Table 14: Reimbursements of anti-cancer drugs ...... 68

LIST OF FIGURES

Figure 1: Changing trends of demographics of Morocco...... 10 Figure 2: Breakdown share of hospital beds (A) in public and private hospitals...... 18 Figure 3: Health care professionals (B) in public and private hospitals...... 18 Figure 4: Financing of total health expenditure in Morocco ...... 19 Figure 5: Intended coverage of population by insurance scheme...... 20 Figure 6: Share of AMO coverage by insurance provider...... 21 Figure 7: CNSS pay-outs for short-term, long-term, and family care (A)...... 23 Figure 8: CNSS beneficiaries receiving short-term, long-term, and family care (B)...... 23 Figure 9: Drug approval and reimbursement process in Morocco ...... 32

1 Executive Summary

The Kingdom of Morocco is a country in the Maghreb region of North Africa. Morocco obtained independence from French rule on 2nd March, 1956. The country has a constitutional monarchy and an elected parliament. The majority of the country’s population belongs to the economically productive age group of 25– 54 years, with the median age of the population being 28.1 years. Nearly 57% of population resides in urban locations. Morocco has capitalized on its proximity to Europe and on its relatively cheap labor force to forge an open market oriented economy. As per 2013 estimates, the national GDP (PPP) stands at USD 180 billion, with an estimated per capita income (PPP) of USD 5,500 and an estimated GDP real growth rate of 5.1%. The majority of GDP comes from services sector and mining. However, agriculture employs a huge work force (40%) while contributing 15% to national GDP. However, the income/wealth distribution has a huge gap with Gini coefficient of 0.41. In terms of its healthcare infrastructure, however, circumstances are not ideal: As per the reports from US government, Morocco has insufficient trained physicians (0.62 per 1,000 people) and hospital beds (1.1 per 1,000 people) for its population. The prevalence of HIV/AIDS in Morocco is comparatively low 0.1% (2012 estimates), indicating the ability of Moroccan MoH in implementing healthcare programs. Over the recent years the data shows that Morocco has achieved significant success in improving maternal and child health. However, for poorer sections of the society access to care is still a problem. The Ministry of Health (MoH), Government of Morocco and the National Health Insurance Agency (ANAM) are the prime regulatory bodies responsible for overall healthcare access and regulations in Morocco. The MoH is responsible for development and implementation of government policy on public health; the Department of Pharmacy of MoH licenses marketing of new drugs in the country based on safety and efficacy data; and ANAM is the main regulatory body governing health insurance schemes in Morocco. Currently, there are two major health insurance schemes in Morocco: AMO (Assurance Maladie Obligatoire) for the salaried public and private sector employees and for self-employed people, and RAMED (Régime d’Assistance Médicale) for the poorer sections of society. Both schemes together cover the healthcare needs of more than 50% of the Moroccan population. Being premium based, AMO insurance provides better health coverage than that of the government funded RAMED insurance scheme. The analysis of the spending under both AMO and RAMED indicates that chronic diseases, though accounting for fewer cases still command the majority of expenses. Public healthcare systems account for the majority of healthcare services (nearly 75% of healthcare in Morocco based on HCPs employed) provided in the country; while the private and non-governmental organization (NGOs) based healthcare systems account for the remaining (~25%). Although public hospitals represent a higher share in terms of number of beds, they receive hardly 10% of insurance spending. This indicates that majority of the patients prefer to attend private

medical hospitals. As per the World Health Organization (WHO), total healthcare expenditure in Morocco amounts to approximately MAD 19 billion (approximately 5% of GDP), of which 51.6% is financed by households independently and 44.4% by collective financing (taxes, insurance, and local authorities). Approval from Dept. of pharmacy, MoH is necessary before marketing any drug in Morocco. If the drug is already approved by one of the Western regulatory agencies (US FDA or EU EMEA), then the approval process for Morocco would be greatly accelerated. For reimbursement decisions, ANAM assesses new drugs based on their safety and efficacy parameters and also based on their cost implications. The physicians generally prescribe the drugs that are reimbursed. However, they do have the liberty to prescribe non-reimbursed drugs, in which case the patient will have to pay for themselves.

2 Country landscape

2.1 Geography

Morocco, also known as the Kingdom of Morocco, is a country in the Maghreb region of North Africa. The country borders the North Atlantic to the northwest, Algeria to the east, and Mauritania to the south. The political capital of Morocco is Rabat; however, Casablanca is the largest city in the nation. Other major cities are Marrakesh, Tangier, Tetouan, Salé, Fes, Agadir, Meknes, Oujda, Kenitra, and Nador. Morocco is divided into 16 regions, which, in turn, are subdivided into 62 prefectures and provinces. [1].

2.2 Economic environment

Morocco has a liberal economy. Its proximity to Europe and relatively low labor costs compared to that of Europe has helped the country to build a diverse, open- market-oriented regime. As per 2013 estimates, the national GDP (adjusted for purchasing power parity, PPP) stands at USD 180 billion, with an estimated per capita income (PPP) of USD 5,500 and an estimated GDP growth rate (real growth rate) of 5.1% (Table 1) [1].

Table 1: GDP Real growth rate of Morocco

Year Real growth rate 2013 5.1% 2012 2.7% 2011 5%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

The majority of the Moroccan gross domestic product (GDP) comes from the services sector (Table 2), followed by industries such as mining and processing (especially phosphates), food processing, leather goods, textiles, construction, energy and tourism. However, Morocco still depends heavily on agriculture: it accounts for ~14% of GDP and employs 40%–45% of population. Due to over dependence on agriculture, economic growth has been erratic and relatively slow (Table 2), depending on the variations in rainfall [1].

Table 2: GDP composition (2012 estimates) by sector of origin

Sector Contribution Labor share Agriculture 15.1% 44.6% Industry 31.7% 19.8% Services 53.2% 35.5%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Inequality, poverty and vulnerability remain important challenges. Morocco’s Gini coefficient (measure of inequality of income distribution among citizens: coefficient of zero means maximum equality while coefficient of 1 or 100% means maximum inequality) of 0.41 reflects high level of inequality in incomes and access to services. With 13.3% of the population still living just above the poverty

line, it also means that a fifth of Morocco’s population (6.3 million people) still lives either in poverty or just above the poverty line. This highlights disproportionate income distribution with low ability to spend for goods and services. Being a country which is largely dependent on the performance of the agricultural sector, the rural populations make up two-thirds of the poor, largely employed in agricultural and informal (including fisheries and forestry) activities. In addition, overall unemployment remains high at around 9%, with urban youth unemployment reaching 35.4%, and labor participation rates among the lowest among emerging economies, with less than half of the population economically active [2]. The United Nations Development Programme (UNDP)’s human development report (HDR) places the human development index (HDI) of Morocco at 0.591, positioning the country at 130 out of 187 countries and territories [3].

2.3 Demographics

The 2014 estimated population of Morocco is about 32.98 million, with a growth rate of 1.02% [1, 2] A majority of this population belongs to the economically With the median age productive age group of 25–54 years (Table 3) [1]. The median age of the group of 28.1 years a population is 28.1 years [1]. The birth rate of population is 18.47 births/1,000 majority (42%) of population, while the death rate is 4.79 deaths/1,000 population [1]. As per 2011 Moroccan population estimates, 57% of the population lived in urban localities in the country’s major belong to the cities with annual rate of urbanization at 1.62%. The major urban cities with their economically population are mentioned in the Table 4 [1]. productive age group of 25-54 years. This As for the age structure, the population under 14 years represented 44.4% in 1960 exemplifies the which changed to 31% in 2004 and will decline to 20.9% in 2030. The population economic potential of of 15-59 years increased from 51.6% in 1960 to 60% in 2004 and will reach 63.8% Morocco in terms of in 2030. The population of 60 and over, which was only 4% in 1960 reached to 8% business in 2004 and will be representing 15.3% in 2030 [4]. In 2030, there will be a opportunities in reversal of the age pyramid with a decline in the proportion of young people (under various sectors. 15 years, who would decrease from 44.4% to 29.8%) and an increase in the proportion of older people from 7% to 15% in 2030 [4].

Figure 1: Changing trends of demographics of Morocco

70 60 50 40 30 20 10 0 1960 2004 2030 < 14 years 15-59 years >60 years

Source: Sante, R.d.M.M.d.l., strategie sectorielle de sante maroc 2012-2016. 2012

The changing trends of demographics in Morocco indicates that the proportion of population which would be economically productive would continue to increase for next 15 years, which in turn would probably translate into better economic prospects for society and increased business opportunities. Furthermore, the increasing percentage of population over the age of 60 years, heralds the diseases and conditions which mainly afflict late age. It also highlights the need for setting up infrastructure to cater for the healthcare needs of elderly. Morocco's official languages are Arabic and Berber. The country's distinctive group of Moroccan Arabic dialects is referred to as Darija. Approximately 89.8%

of the whole population can communicate to some degree in Moroccan Arabic. While, Arabic is the official language of Morocco, French is generally used in Government, diplomacy, and in business [1].

Table 3: Demographic breakdown of Morocco based on 2014 estimates

Age group Percentage of Male Female (years) population (%) 0–14 26.7% 4,479,676 4,342,605 15–24 17.7% 2,899,041 2,931,856 25–54 42.0% 6,693,877 7,146,696 55–64 7.3% 1,200,733 1,203,447 65 and above 6.3% 940,291 1,148,984

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Table 4: Major urban cities and their population based on 2011 estimates

City name Estimated population Casablanca 3.046 million Rabat 1.843 million Fes 1.088 million Marrakech 939,000 Tangier 810,000 Agadir 805,000

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Education in Morocco is free and compulsory through primary school. As per 2011 estimates the literacy rate among 15 years and above who can read and write was 67.1% (male: 76.1%; female: 57.6%). The average school attendance is 11 years (male: 12 years; female: 11 years). The unemployment rate among youth of ages 15 to 24 years is 18.6% (male: 18.4%; female: 19.2%) (Table 5) [1].

Table 5: Educational parameters

Parameter Rate Male Female

Literacy rate 67.1% 76.1% 57.6% (15 years and above)

School attendance 11 years 12 years 11 years (years)

Unemployment rate 18.6% 18.4% 19.2% (15 to 24 years)

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Morocco has several universities, institutes for higher learning, and polytechnics. The leading institutions in Morocco include Mohammed V University in Rabat (the country’s largest university, with branches in Casablanca and Fès), the Hassan II Agriculture and Veterinary Institute in Rabat (conducts social science research and agricultural research), and Al-Akhawayn University in Ifrane (the first English-language university in North Africa, inaugurated in 1995) [1]. The al- Qarawiyin University, founded in the city of Fez in 859 AD as a madrasa, is considered by some sources, including UNESCO, to be the oldest active university of the world. As per 2009 data Morocco spends 5.4% of its GDP on education which points towards the availability of relatively skilled resources which can fuel the country’s economy.

2.4 Political structure and environment

Morocco obtained independence from French rule on 2nd March 1956. Morocco has a constitutional monarchy and an elected parliament. The King of Morocco holds executive and legislative powers, over the military, foreign affairs, and religious matters. However, executive power is mainly exercised by the elected government, while legislative power is vested in both the government and the two chambers of parliament, the Assembly of Representatives and the Assembly of Councilors [5]. Morocco has an independent judiciary: the Supreme Court or Court of Cassation which consists of 5-judge panels organized into civil, family matters, commercial, administrative, social, and criminal sections. The Supreme Court judges are appointed by the monarch based on the recommendations of the Supreme Council of the Judiciary. The subordinate courts include courts of appeal; regional and sadad courts (for religious, civil and administrative, and penal adjudication) (2). Morocco has been given the status of non-NATO ally by the US government. Morocco is included in the European Union's European Neighborhood Policy which aims at bringing the European Union (EU) and its neighbors closer.

3 Healthcare infrastructure

As per the reports from US government, Morocco has insufficient trained physicians (0.62 per 1,000 people) and hospital beds (1.1 per 1,000 people) for its population [1]. Access to safe drinking water and improved sanitation facilities are still poor especially in rural areas (Table 6).

Table 6: Access to safe drinking water and sanitation

Parameter Urban Rural Total

Drinking water 98.5% 63.6% 83.6% (Improved)

Drinking water 1.5% 36.4% 16.4% (Unimproved)

Sanitation 84.5% 63.1% 75.4% (Improved)

Sanitation 15.5% 36.9% 24.6% (Unimproved)

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

Improved drinking water: piped water into dwelling, yard, or plot; public tap or standpipe; tubewell or borehole; protected dug well; protected spring; or rainwater collection. The healthcare situation in Morocco Improved sanitation: use of any of the following facilities: flush or pour-flush to a is poor; with over piped sewer system, septic tank or pit latrine; ventilated improved pit (VIP) 0.62 physicians per latrine; pit latrine with slab; or a composting toilet. 1,000 population, Morocco has far less Unimproved drinking water: unprotected dug well; unprotected spring; cart with number of physicians small tank or drum; tanker truck; surface water, which includes rivers, dams, than the WHO lakes, ponds, streams, canals or irrigation channels; or bottled water. prescribed standard Unimproved sanitation: use of any of the following facilities: flush or pour-flush of 2.3. not piped to a sewer system, septic tank or pit latrine; pit latrine without a slab or open pit; bucket; hanging toilet or hanging latrine; shared facilities of any type; no facilities; or bush or field. The prevalence of HIV/AIDS in Morocco is comparatively low 0.1% (2012 estimates) [1], indicating the successful of implementation of AIDS prevention programs. The contraceptive usage rate is nearly 67%. Over recent years the coverage of prenatal care has improved significantly; the proportion of women who had at least one pre-natal consultation has increased from 67.8% in 2004 (85% in urban areas and 48% in rural areas) to 80% in 2010 (94% urban and 68% rural), and the proportion of births attended by skilled personnel has increased from 63% in 2004 to 77.1% in 2011 [4]. These data points showcase the success

achieved in improving maternal and child healthcare both in terms of improvement of infrastructure and health access. However, for poorer sections of the society, access to care is still a problem. In Morocco, most of the urban population lives less than 5 km from a healthcare facility, whereas in rural areas, only 30% of the population are less than 5 km from a healthcare facility, 59% live between 5 and 10 km, and 11% live more than 8 km (MoH 2010) [6]. As per 1992 study on the morbidity burden, Morocco faces a triple health challenge: infectious diseases (including maternal and child health) 33.4%; non- communicable diseases 55.8% and trauma 10.8% [4]. The country also faces problems of malnutrition (3.1% children below 5 years as per 2011 estimates) and adult obesity (16.4% as per 2008 estimates) [1]. According to National Population and Family Health survey in 2011, the proportion of children who suffer from, underweight, acute malnutrition and chronic malnutrition are respectively is 3.1%, 2.3% and 14.9% [4]. Tuberculosis, leishmaniasis, community bacterial meningitis and zoonosis still remain major public health problems [4]. According to WHO, as per 2011 data, the burden of disease attributable to environmental degradation in Morocco is 18% of the total disease burden, which is equivalent to 30 DALYs (Adjusted Life Years by disability) lost to 1000 population per year, and 32,000 premature deaths per year [4]. All these above factors indicate the current health burden of Morocco, the possible focus of healthcare reforms and opportunities for private enterprises. Some of the healthcare indicators of Morocco are mentioned in Table 7.

Table 7: Healthcare indicators of Morocco

Parameter Data Mean age of mothers at 1st birth 25.4 Total fertility rate 2.15 children born/woman Life expectancy at birth 76.51 Maternal mortality rate 100 deaths/100,000 live births Infant mortality rate 24.52 deaths/1,000 live births Contraceptive prevalence rate 67.4% Healthcare expenditure (2011 est) 6% of GDP Physician density (2009 est) 0.62 physicians per 1,000 population Hospital bed density (2009 est) 1.1 beds per 1,000 population Inhabitant per public sector doctor 2,900 Inhabitant per private sector doctor 3,693 Inhabitant per hospital bed 1,150 (public sector) • Illnesses of the circulatory system: 22.14% • Tumours: 11.04% The main causes of mortality reported • Certain illnesses linked to the in 2007 perinatal period: 8.84% • Endocrine, nutritional and metabolic illnesses: 6.3%. • BCG: 98.4% Vaccination coverage (in %) of • MMR: 90.4% children of 12 to 23 months • Completely vaccinated children: 89.1%

Source: book, C.T.W.F. Morocco. [cited 2014 24th July]

3.1.1 Healthcare system

The Ministry of Health (MoH) is responsible for the development and implementation of government policy on population health. The MoH works in conjunction with relevant departments to promote health at a national level. This is very significant because the public healthcare system (health care resources of the Ministry of Health, the Royal Armed Forces, Local Communities and other Ministerial Departments) accounts for the majority healthcare services provided in the country (Table 8) [6, 7]. In order to improve the healthcare in Morocco the government has come up with a sector wise strategy for the period of 2012 to 2016 [4]. Under this program the

main areas of actions are restructuring of medical emergencies, improvement of communicable and non-communicable disease management including mental health and cancers, consolidation of rural health, fight against maternal and infant mortality, increasing access of RAMED insurance (medical assistance scheme for poor people), improving human resource management and upgrade of hospitals. The development of a national drug policy and review of drug prices are also among the priorities [4] of MoH. Healthcare in Morocco is generally provided via three strategies: fixed, mobile, and roaming. In the fixed strategy, the patient approaches a basic healthcare provider. The mobile and roaming strategies are implemented to cover the rural regions. In the mobile healthcare strategy a medical team periodically visits areas located far from health centers. In the roaming strategy, a nurse or a health worker visits far flung areas to distribute certain medicines like oral rehydration sachets, contraceptive pills, eye cream, etc. and to promote healthcare procedures for pregnant women, diabetics, and other chronic diseases. The public healthcare delivery system in Morocco can also be categorized into different levels depending on the level of expert services provided by the hospital [6]. There are 2,626 basic health centers, 138 hospitals, 97 general hospitals, 37 specialized hospitals, and 4 university medical colleges (at Rabat, Casablanca, Fez, and Marrakech). The public health service infrastructure comprises 27,350 beds and 38,000 healthcare professionals (HCPs) [6]. The private medical establishments approximately include 220 clinics, 30 dialysis centers, and about 100 radiologist’s offices, which together account for 6,156 beds and 10,800 HCPs [6]. The private non-profit healthcare delivery structure accounts for only a minor share of healthcare delivery in Morocco (1,874 beds) (Table 8) [6].

Table 8: Breakdown of healthcare delivery in public and private sectors

Healthcare Hospital beds, Sector professionals n (%) employed, n (%) Public 27,350 (77%) 38,000 (78%) Private 6,156 (18%) 10,800 (22%) Public autonomous and NGOs 1,874 (5%) NA

Source: WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]

Figure 2: Breakdown share of hospital beds (A) in public and private hospitals

Public Private sector, autonomous 6,156 (18%) and NGOs, 1,874 (5%)

Public sector, 27,350 (77%)

Source: WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]

Figure 3: Health care professionals (B) in public and private hospitals

Private sector, 10,800 (22%)

Public sector, 38,000 (78%)

Source: WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]

The Basic Healthcare Centers provide health and hygiene services to the population in both rural and urban areas. The different activities or services that are Morocco has an provided in these centers include: birth assistance, dental consultations and dental elaborate network of care, emergency care, general medical consultations, hospitalization, laboratory primary healthcare examinations, mental health, radiological examinations, school hygiene, centers to tertiary specialized medical consultations, testing and water treatment [6]. hospitals. Public hospitals account for As per the World Health Organization (WHO), based on data of year 2000, the majority of total healthcare expenditure in Morocco amounts to approximately MAD 19 billion healthcare in (i.e., ~5% of GDP), of which 51.6% is financed by households (out of pocket) Morocco. independently and 44.4% by collective financing (taxes, insurance, and local authorities) (Figure 4) [7]. At the end of 2008, the total healthcare expenditure in

Morocco was USD 4.3 billion for the year, which was 5.6% of the GDP [6]. The analysis of spending shows that the national healthcare system spends more than 33.6% of its monetary resources on buying medicine and medical goods indicating the enormous potential for the pharmaceutical industry. Ambulatory care, including health promotion check-ups and external consultations, represents 35.2% of spending [6].

Figure 4: Financing of total health expenditure in Morocco

Total health expenditure 4% USD 2.31 billion

44% 52%

Households Taxes, insurance, local government Other

Source: WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]

MoH has a national sanitary information system (SNIS) for gathering information and managing maternal and childhood health programs [8]. It is a computer program-based, system which allows data entry and validity, synthesizing graphs for different activities as well as a control panel for decision making. The data transmission from basic health structure to central level is made electronically, which are accessible for consultation to all structures of the Health Ministry. However, there seems to be a lack of integration of different health information and management systems [8].

4 Market access 4.1 Health insurance system

The MoH offers the entire population access to clinics, health centers, dispensaries, diagnostic centers, and public hospitals [9]. All Moroccans are eligible to receive care at MoH facilities. Through their local government, the poor can obtain a certificat d’indigence, which permits them to receive free care at public health facilities [9]. Those who are not eligible to receive certificat d’indigence can also receive subsidized healthcare at MoH facilities. However, concerns exist over the quality of care at these facilities, and hence people tend to prefer private healthcare providers. The government of Morocco has initiated two major healthcare insurance packages: AMO and RAMED. The Assurance Maladie Obligatoire (AMO) is a payroll-based mandatory health insurance plan for public and formal private-sector employees. The Régime d’Assistance Médicale (RAMED) is a publicly financed fund to cover healthcare services for the poor. Both reforms are aimed at improving the access to healthcare [9]. In 2007, INAYA was introduced as a scheme that would fill the gaps left by AMO and RAMED; it provided coverage to the self-employed population. Each of these schemes are intended to cover nearly one-third of the Moroccan population (Figure 5) [7]. However, of recently INAYA is being merged with AMO. The regulatory body overseeing the operations of health insurance schemes in Morocco is Agence Nationale de l’Assurance Maladie (ANAM; English: National Health Insurance Agency) [7].

Figure 5: Intended coverage of population by insurance scheme

Others 5%

AMO 34% INAYA 31%

RAMED 30%

Source: WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]

4.1.1 AMO: Mandatory health insurance (Assurance Maladie Obligatoire)

AMO is a basic medical coverage (insurance) scheme under law No 65-00; it is the basis of social health protection in Morocco. The scheme came into effect on January 4, 2005 [7]. The beneficiaries under AMO include: • Officials and civil servants of the state, local authorities, public health facilities, and corporations registered under public law • Persons subject to the social security scheme in the private sector • Pensioners in both the private and public sectors

Currently, there are more than 6,000,000 members and over 8,600,000 beneficiaries (4,600,000 in the private sector and 4,000,000 in the public sector), excluding former resistance fighters, students, etc. AMO is managed by the Caisse nationale de Sécurité Sociale (CNSS; English: National Social Security Fund) for nearly 2,800,000 private sector employees, and, by private insurance companies for the remainder 1,800,000 private sector employees. Caisse nationale des Organismes de Protection Sociale (CNOPS; English: National Fund for Social Welfare Bodies) provides AMO health insurance to nearly 3,200,000 public sector employees, while the Royal Armed Forces cover the 800,000 military personnel (Figure 6) [7].

Figure 6: Share of AMO coverage by insurance provider

800,000 , 9%

2,800,000 , 33%

3,200,000 , 37%

1,800,000 , 21%

CNSS Private sector insurers CNOPS Royal Armed Forces

Source: WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]

For insured persons and their dependents, AMO guarantees coverage for the risks and costs of healthcare associated with disease or accidents, maternity, and physical or functional rehabilitation. More specifically, AMO covers all the following for both the public and private sectors [7]: • Childbirth • Medical/surgical hospitalization, including day care services • Management and follow-up care of long-term conditions and long and expensive conditions • Monitoring of pregnancy, delivery, and postpartum care • Well-child care up to the age of 12 • Medical devices and implants required for different medical and surgical procedures • Refundable prosthetic devices and braces • Refundable medicines required for the above care

For the public sector employees, the package also includes outpatient care and examination (medical consultations, laboratory tests, medical imaging/functional explorations, medicines, etc.). The funding for the insurance premiums is equally shared between employer and employee up to a fixed ceiling. Care is billed on the basis of national reference fees and tariffs set by ANAM. Furthermore, CNSS owns a chain of polyclinics: with 1000 hospital beds, 42 operating rooms, 11 maternity centers, 13 ICUs, 9 dialysis centers, 13 medical laboratories, 137 medical imaging scanners, 1 neonatal resuscitation department, 2 cardiology intensive care units, and 10 rehabilitation units. CNSS hospitals are open to all patients and those insured by the various private companies. As per 2012 data, almost 29% of CNSS beneficiaries were under long-term care (Figure 7 & 8), and this long-term care accounted for 61% of the total benefits paid out by CNSS (Figure 7 & 8) [10].

Figure 7: CNSS pay-outs for short-term, long-term, and family care (A)

35% Long term care Short term care

61% Family care

Source: CNSS, M. Key figures. 30th April, 2014]

Figure 8: CNSS beneficiaries receiving short-term, long-term, and family care (B)

29% Long term care Short term care Family care 64% 7%

Source: CNSS, M. Key figures. 30th April, 2014]

Financially, the income of the two insurance organizations (CNSS, CNOPS) for employees stands at (for the year 2012) 8.11 billion MAD, but they spend about 5.30 billion MAD on benefits. Majority of the expenditure happens for the long- term conditions (ALD) and lengthy and costly diseases (ALC), which alone constitute more than 50% of overall spending. The breakdown of revenue and expenditure per organization is given in Table 9 [11]. The major expenses under AMO are accounted by medications (33%), hospitalizations (16%) and dialysis (12%) [11]. These cost factors indicate that chronic diseases while accounting for fewer cases still command higher expenses. With the majority of the population shifting to middle and old age in coming decades, the burden of chronic diseases is expected

to increase in Morocco: healthcare funding should follow. Providing appropriate healthcare solutions to long term conditions of cardiovascular, diabetes, cancers and autoimmune conditions would become a focus for MoH in coming near future and also would provide opportunities for private enterprises.

Table 9: Breakdown of income and major expenditure of CNSS and CNOPS for 2012

Parameter CNSS CNOPS Total Income 3.767 4.340 8.107 (billion MAD) Planned expenditure 1.795 3.506 5.301 (billion MAD) Spending for 58.7% 45.9% 49.9% ALD/ALC

Drug expenditure 33.3% 33.4% 33.3%

Source: ANAM, Roadmap 2014-18. 2014

4.1.2 RAMED: Medical assistance scheme (Régime d’Assistance Médicale)

RAMED is a basic medical coverage scheme intended for deprived sections of the society; it was introduced in 2002 under law No 65-00. Under this scheme, individuals with a certificat d’indigence (English: certificate of indigence) can access free care at public healthcare and hospital facilities. Under RAMED, households with an income of less than MAD 300 (US$34) per capita per month will be eligible for free health insurance. Households with monthly per capita income of MAD 300–600 (US$34–$68) will purchase insurance based on a slab scale. To protect the poor from financial burden, there are no caps on coverage [9]; however, they can only access care at public healthcare hospitals. The following categories of people are eligible for RAMED [7]: • Persons not covered by a basic AMO scheme and without sufficient resources to meet the costs of medical care for themselves and/or their spouse(s) • Dependents, that is, non-wage earning children aged up to 21, who are not otherwise covered by the basic AMO scheme (age limit may be extended up to 26 in the event of prolonged illness with adequate justification)

• Children with physical disabilities, irrespective of age, who are totally and permanently unable to fulfil a remunerated activity as a result of a physical or mental incapacity • Residents of charitable institutions, orphanages, hospices, rehabilitation facilities, and any non-profit public or private care facility accommodating abandoned children or adults with no family • Prisoners • Persons who have no permanent place to reside

The estimated population eligible under RAMED is at 8.5 million, including 4 million in absolute poverty. The scheme is managed and regulated by ANAM. Financially, the income of the RAMED insurance scheme stands at (for the year 2012) 1.9 billion MAD, while spending about 1.06 billion MAD on benefits. The major contributors for RAMED funding are local authorities (177 million MAD), vulnerable population/beneficiaries (136 million MAD) and government (1,611 million MAD). Just like under AMO the majority of the expenditure under RAMED happens for the long-term conditions (ALD) and lengthy and costly diseases (ALC), which alone constitute more than 50% of overall spending. This again highlights the economic burden imposed by chronic medical conditions which need early diagnosis and management in order to prevent cost overruns in late stages: an opportunity for relevant players in the healthcare industry. The breakdown of revenue and expenditure per organization is given in Table 10 [11].

Table 10: Breakdown of income and major expenditure of RAMED for 2012

Parameter RAMED Income (billion MAD) 1.924 Planned expenditure 1.065 (billion MAD) Spending for ALD/ALC 31%

Source: ANAM, Roadmap 2014-18. 2014

4.1.3 INAYA: Health insurance for the self-employed

INAYA was introduced in 2007 to fill in the gaps left by the existing AMO and RAMED schemes. Now this scheme is being merged with AMO. INAYA scheme was aimed at providing health coverage to the self-employed (craftsmen and retailers with or without business premises and their assistants) and freelance professionals. The estimated population eligible under the scheme is around 10

million [7]. Considering the fact that self-employed people constitute nearly one- third of the Moroccan population, this process constitutes a major expansion of the healthcare insurance system in Morocco [12]. Funding for this scheme is expected to come from the premiums to be paid by the beneficiaries. The population covered by health insurance reached 10.8 million beneficiaries by 2012, or 33.7% of Morocco's population, as against 25% in 2006. The insurance Morocco has an management bodies spent 8.2 Billion MAD (excluding administrative costs), or elaborate system of health insurance 762 MAD/ year per beneficiary, as against 602 MAD/ year per beneficiary in 2006 schemes. These [4]. However, the public hospitals, despite representing more than 80% of national schemes though bed capacity, only receive 9.8% of insurance spending in the context of direct successful yet need payments and 6.6% of the total health insurance spending [4]. Furthermore, the to cover nearly 50% rural areas are facing a human resource crunch as the majority of healthcare of population. professionals (22% of public physicians and 50% of private physicians) are Majority of insurance concentrated in Greater Casablanca and Rabat areas [4]. expenditure is incurred on long term care.

4.2 Drug prescribing and dispensing practices

The physicians generally prescribe the drugs that are reimbursed. However, they do have the liberty to prescribe non-reimbursed drugs, in which case the patient will have to pay for themselves. There are also situations wherein the physician has to prescribe drugs that are not yet licensed in Morocco and that will have to be imported, however, with special approval from the MoH. In such cases, the physician must be able to justify his decision with evidence of efficacy and benefit for the patient. At public hospitals, an in-house pharmaco-vigilance committee assesses the need for new drugs and recommends them to the MoH for purchase. The drug, if approved, would then be purchased by the MoH for the hospital [12]. However, in the private sector, the patients are left to find and purchase the drug themselves from a private pharmacy. As per law, the health insurance providers and NGOs are not supposed to provide drugs themselves [12].

4.3 Comparison of regional regulatory agencies and environment

Medicine Regulatory Agencies (MRA) in Africa face significant challenges in meeting their mandate. Their pharmaceutical regulatory capacity is below that of Europe, Latin America, and Asia. A 2004 WHO study reported that 90% of African MRAs lacked sufficient capacity to guarantee the quality, efficacy, and safety of medicines in their country [13]. A study conducted by WHO in 2006 concluded that among African countries, only South Africa had a fully functional MRA. The MRAs of Nigeria, Zimbabwe, Senegal, Tunisia, Morocco, and Algeria were functional but needed strengthening in regulation of clinical trials. The MRAs of Ghana, Egypt, Uganda, and Ethiopia had “potential“ although they were not yet fully functional [13]. African MRAs traditionally have focused on assessment of generic products. For the review of innovative products they have relied mainly on Western MRAs [14]. However, off recently more and more products are being developed specifically for the African market. This has put African MRAs under pressure to develop their skills and capabilities in regulatory services. In general, a drug that is already approved by one of the western MRAs (such as the European Union (EU)’s EMEA or the US FDA) will find it comparatively easier to receive approval in Morocco as well. Given the absence of well-established MRAs in the African countries, pharmaceutical product development companies/organizations use various alternative routes for registration of generic/innovative drugs [14]. i. Western regulatory approval • Routine regulatory approval The majority of new products are first registered with well-established Western regulatory authorities (US FDA, EU EMEA, UK Medicines etc) even for the products that are likely to have little or no use in the West but are crucial for developing countries. Under this approach, companies wait for FDA or EMEA approval following which they submit the dossier to African MRAs for approval. • Orphan drug legislation Orphan drug legislation in the US, EU, Japan, and Australia provides incentives for manufacturers to develop drugs for diseases that have too few patients to constitute a profitable market. Under this channel approvals may be given even without large-scale clinical trials. • Expedited approvals

o Accelerated approval (US FDA)/ Conditional approval (EU EMEA) o Priority review (US FDA)/ Fast Track (EU EMEA)

o Fast Track (US FDA) ii. Neglected disease specific pathways • EMEA Article 58 This mechanism was established by the European Commission in 2004 to facilitate developing-country registration of medicines of major public health interest, and not for a formal registration.

• WHO prequalification This initiative was started in 2001 as a means to assure the quality of drugs procured through the UN system. Many African MRAs rely heavily on the WHO drug pre-qualification system as a proxy dossier assessment and, in some cases, the MRA quickly approve products that have received WHO prequalification. The program was earlier stipulated for drugs for HIV/AIDS, malaria, and tuberculosis; however, it has now invited companies to submit products for reproductive health, influenza, and zinc supplements.

• US FDA “tentative approval” and PEPFAR As part of the US President’s Emergency Plan for AIDS Relief program (PEPFAR), the US FDA would evaluate the safety, efficacy and quality of HIV drugs purchased with PEPFAR funds for use outside the US. iii. Alternative regulatory pathways • Parallel Western and developing country approval Under this the companies submit full dossiers to the Western regulator and developing country MRAs, both of who conduct their regulatory reviews simultaneously but independently. • Twinned Western and developing country approval Twinned review refers to a process whereby a developing country regulator would assess a pharmaceutical dossier in consultation with, a well- resourced western regulatory agency. • First approval by a developing country regulator Under this approach, the company submits the dossier first to a developing country regulator, usually their home regulator. • WHO vaccine prequalification The WHO Vaccine Prequalification program was set up in 1987 as a service to UNICEF and other UN vaccine procurement agencies. It aims to

determine that products bought by these agencies and used in national immunization services are safe, effective, and meet operational and quality standards. The African governments rely heavily on WHO vaccine pre-qualification.

The complex African regulatory environment had led to difficulties in optimal use of resources by the MRAs. Therefore, a great deal of effort is being committed to African regulatory harmonization. To this end, various communities are being formed, including the following [13]:

4.3.1 Southern African Development Community (SADC):

SADC was formally established by treaty in Namibia on August 17th, 1992. It consists of 15 member states (Angola, Botswana, Democratic Republic of the Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe), and aims to share resources and expertise among various MRAs, provide training, develop guidelines, harmonize clinical trials etc. [13].

4.3.2 Economic Community of West African States (ECOWAS):

ECOWAS is a West African Drugs Regulatory Authority Network (WADRAN) of Anglophone and francophone West African states for fighting counterfeit medications, evaluating dossiers, and conducting Good Manufacturing Practices investigations and surveillance after registration of drugs [13].

4.3.3 East African Community (EAC):

EAC is working toward harmonization of drug registration procedures as an objective to achieve good pharmaceutical standards without posing an obstacle to the free movement of pharmaceutical products [13].

4.4 Drug approval and reimbursement process in Morocco

Any drug, either produced locally or imported, even at the sample level, must obtain authorization from the Department of Pharmacy, MoH, prior to sale or distribution (even for free) [15]. Moreover, this authorization is necessary before any drug can be considered for reimbursement. The MoH states that authorization can only be issued if the drug meets certain prerequisites for appropriate testing to highlight efficacy, ensure its safety under normal conditions of use, demonstrate its therapeutic value, and establish bioequivalence when it comes to a generic drug. Thus, the manufacturer can show the clinical trial data of the drug to showcase its safety and efficacy parameters [15]. However, if the drug has already been proven to be efficacious and has been approved by one of the Western regulatory agencies (US FDA or EU EMEA), then the approval process for Morocco will be greatly accelerated. The intellectual property protection laws in Morocco are comparatively better; a generic drug can only be sold when the patent of the reference drug expires [15]. ANAM is the regulatory agency responsible for insurance reimbursement in ANAM is the key Morocco. For a new drug to be approved for reimbursement, it must pass through regulatory body two stages of evaluation. First, ANAM’s Transparency Committee assesses new tasked with approval drugs based on their efficacy and superiority to existing strategies of treatment. of new drugs and The Transparency committee assesses new drugs based solely on efficacy and with approval of safety parameters and not based on cost parameters. The committee accepts the reimbursement for clinical trial data from other countries and it is not necessary in every case to drugs. conduct a study in the host country for drug reimbursement. If the application passes this stage, it is sent to the Economic Committee to assess the cost implications. The recommendations of both committees are taken into account before ANAM submits reimbursement recommendations to the MoH for approval. Currently, of the approximately 5,000 drug formulations approved for distribution in Morocco, reimbursement is available for 3,000 drug formulations [12]. While the Economic Committee falls directly under the purview of ANAM, the Transparency Committee is an independent body associated with ANAM. The members of the Transparency Committee include a president and vice-president, who are appointed by the MoH; representatives from the National Organization of Humanity and Ethics and from the Ethics Organization of Physicians and Pharmacists; the Department of Pharmacy and Drugs; and four independent expert physicians nominated by ANAM [12]. The expert physicians are permanent members, but can recommend other external experts, if a certain drug is outside their scope of expertise. Drug prices in Morocco are controlled and the policy guidelines tend towards lower prices for certain important therapeutic classes. Generally, drugs that could have a major impact on key public health issues can be expected to suffer significant cost pressures. If the price of the drug is beyond the scope of the planned budget, then the committee might ask the manufacturer to reduce the price [12]. However, the MoH is currently proposing a new system to [15]:

• Establish an updated regulatory framework for products with local manufacturing and imported products • Improve access to medicines while containing costs • Provide solutions to national pharmaceutical environment

Figure 9: Drug approval and reimbursement process in Morocco

• Authorization is Any drugs, either necessary before produced locally or any drug can be imported must obtain considered for authorization before Apply for approval from reimbursement marketing. Post- Dept. of pharmacy, MoH Clinical trial data approval drug can be • marketed in the from other countries country. will be considered for approval

ANAM is the regulatory agency Reimbursement • Assesses new drugs responsible for application to ANAM on their safety, insurance reimbursement in efficacy and Morocco. superiority to Assessment of new drugs existing strategies for reimbursement is of treatment made by two • Prior clinical trial committees: the data would be Transparency committee helpful at this stage and the Economic Transparency committee committee. of ANAM

• Assessment of cost implications of reimbursements Based on • If the price of the recommendations from drug is beyond the Transparency committee scope of the of ANAM the Economic committee of planned budget, application is forwarded ANAM then the committee to Economic committee. might ask the manufacturer to reduce the price

• Price negotiations

The approval of new The recommendations of drug for reimbursement both Transparency and is based on safety, Economic committees efficacy, superiority and sent to MoH for approval. MoH approval cost. Even costly drugs are reimbursed.

Source: CNSS, M. Key figures. 30th April, 2014]

5 Conclusion

Morocco, officially known as the Kingdom of Morocco, is a constitutional monarchy with an elected parliament in the Maghreb region of North Africa. The majority of its population belongs to the economically productive age group of 25– 54, which also makes the country economically robust. In Morocco, public healthcare systems account for the majority of healthcare services provided. However, organized-sector workers such as private and public sector employees prefer private clinics over public hospitals, as they are reimbursed under the AMO scheme. It is in private hospitals that the majority of insurance reimbursement happens. The poor (those holding a certificate of indigence) are provided free medical care at public hospitals under RAMED, which is financed directly by the government. However, the healthcare services under RAMED are limited as compared with those under AMO, and, moreover, RAMED does not provide reimbursement, only free treatment. Nearly 50% of Moroccans are covered by some form of medical insurance (~30% by AMO and ~20% by RAMED). Despite that, nearly half of the healthcare expenditure in Morocco is still out-of-pocket, as the health insurance framework is not yet completely established. With the majority of the population shifting to middle and old age in coming decades, the burden of chronic diseases is expected to increase in Morocco, so healthcare funding should do the same. Providing appropriate healthcare solutions to long term conditions of cardiovascular, diabetes, cancers and autoimmune conditions would become a focus for MoH in coming near future and also would provide opportunities for private enterprises. Regardless of the inaccuracies in health insurance, approval for reimbursement (especially for costly and specialized therapeutics) still represents a major advantage toward achieving patient access. Furthermore, as Morocco does not have a well-established MRA, approval by a Western agency (e.g., US FDA or EU EMEA) is a very good first step toward securing approval for marketing in Morocco. An added advantage is that the Moroccan MRA, that is the Department of Pharmacy of the MoH, will approve drugs on the basis of clinical trials conducted outside the country. Physicians generally prescribe the drugs that are reimbursed. However, they do have the liberty to prescribe non-reimbursed drugs and in such cases the patient will have to pay out of their pocket for the medications. Our analyses of the current healthcare activities in Morocco and the general trends in emerging markets shows policy makers and patient bodies are demanding greater influence in the drug selection process. As a result, a collaborative approach needs to be promoted to outline and manage public policies. It is important for each stakeholder to include scientific and rational data to support their issues and concerns. This is of particular importance in countries like Morocco, where the MoH and ANAM evaluate drugs on both efficacy and economic impact.

6 Appendix

6.1 Glossary

ALD (French) : long-term conditions ALC (French) : lengthy and costly diseases AMO : Moroccan mandatory health insurance scheme (Assurance Maladie Obligatoire) ANAM : Moroccan National Health Insurance Agency (Agence Nationale de l’Assurance Maladie) ASR : age-standardized rate BCG : Bacillus Calmette-Guerin vaccine for tuberculosis CNOPS : Moroccan National Fund for Social Welfare Bodies (Caisse nationale des Organismes de Protection Sociale) CNSS : Moroccan National Social Security Fund (Caisse nationale de Sécurité Sociale) EAC : East African Community ECOWAS : Economic Community of West African States ESMO : European Society for Medical Oncology EMA : European Medicines Agency EU : European Union FSRC : focus scientific research center GDP : gross domestic product HCP : healthcare professional HDI : human development index HDR : human development reports INAYA : Moroccan health insurance scheme for self-employed MAD : Moroccan dirham MMR : Measles Mumps and Rubella vaccine MoH : Moroccan Ministry of Health MRA : Medicine Regulatory Agencies NATO : North Atlantic Treaty Organization NGO : non-governmental organization PEPFAR : US President’s Emergency Plan for AIDS Relief

PET : positron emission tomography PPP : purchasing power parity RAMED : Moroccan publicly financed fund for healthcare services to the poor (Régime d’Assistance Médicale) SADC : Southern African Development Community UNDP : United Nations Development Programme UNESCO : United Nations Educational, Scientific and Cultural Organization US : the United States of America USD : United States dollar FDA : Food and Drug Administration (US) WHO : World Health Organization

6.2 Coverage rates for long-term and costly conditions

Table 11: Coverage rates for long-term and costly conditions

New reimbursement Long lasting diseases Diseases rate Malignancies Malignancies 95% Malignancy of the lymph tissue or Malignancy of the lymph tissue or 95% haematopoietic tissue haematopoietic tissue Liver cirrhosis Liver cirrhosis 97% Active chronic liver disease Active chronic liver disease 97% (Hepatitis B and C) (Hepatitis B and C) Terminal stage of renal disease Terminal stage of renal disease 98% Severe Aplastic Severe Aplastic 99% Hereditary bleeding disorders Hereditary bleeding disorders 97% Severe myelodysplasia Severe myelodysplasia 94% Multiple Sclerosis Multiple Sclerosis 96% Stroke or ischemic or haemorrhagic Stroke or ischemic or haemorrhagic 90% medullary medullary Severe chronic respiratory Chronic respiratory insufficiency 90% insufficiency Stable angina 85% Revascularized coronary 85% Coronary disease (Angioplasty or bypass) Unstable angina or syndrome 85% Acute Myocardial Infraction (MI) 85% Thalassemia major 96% Homozygous sickle cell 96% Chronic hemolytic anemia severe Chronic autoimmune hemolytic 96% anemia Moderate to severe chronic asthma 90% Severe asthma Severe asthma episodes 90% Acute Severe Asthma 90%

New reimbursement Long lasting diseases Diseases rate Rheumatoid arthritis severe Rheumatoid polyarthritis 93% progressive Glomerulonephritis 96% Pyelonephritis 96% Renal interstitial 96% Severe kidney disease Renal vascular 96% Hereditary kidney disease or 96% congenital Nephrotic syndrome Nephrotic syndrome 96% Acute renal failure Acute renal failure 95% Left ventricular failure 83% Heart failure Right ventricular failure 83% Ulcerative colitis Ulcerative colitis 81% Crohn`s disease Crohn`s disease 81% Systemic lupus erythematosus Systemic lupus erythematosus 97% Severe epilepsy 97% Severe epilepsy Status epilepticus 97% Progressive systemic sclerosis Progressive systemic sclerosis 91% Vasculitis Vasculitis 93% Mental disorders and /or personality Mental disorders and /or personality due to an injury, a brain dysfunction due to an injury, a brain dysfunction 83% or physical injury or physical injury HTA with high CV risk 77% Hypertension with LVH 77% HTA with IC 77% High blood pressure (hypertension) HTA with myocardial ischemia 77% severe HTA with IR 77% Hypertension with hypertensive 77% retinopathy HTA with ATCD stroke 77%

New reimbursement Long lasting diseases Diseases rate HTA with ATCD transient ischemia 77% With arterial hypertension Member 77% lower MM hereditary myopathy 85% MM Inflammatory Myopathy 85% MM Myasthenia 85% MM SD Lambert-Eaton 85% The MNP-polyneuritis 85% Severe forms of the neurological MNP-Multiple mononeuropathy 85% and neuromuscular disease MNP-polyradiculoneuritis 85% MNP-Hereditary neuropathy 85% The spastic paraparesis MMCA- 85% family MMCA-Charcot’s disease (ALS) 85% The hereditary ataxias MMCA 85% Mental retardation 83% Acquired dementia :Alzheimer’s State mental deficit 83% disease Secondary dementias 83% Glaucoma Glaucoma 83% Acquired Immunodeficiency Acquired Immunodeficiency 85% Syndrome (AIDS) Syndrome (AIDS)

Source: ANAM website; http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=18#38

Table 12: Coverage rate of lasting and costly disorders

Procedure Break down Coverage rate

Kidney 100%

Liver 100%

Organ transplantation Heart 100%

Cornea 100%

Bone Marrow 100%

Rheumatic valvular 100%

Congenital heart 100%

Cardiac surgery Coronary disease 100%

Laying Pace Maker 100%

Chronic arterial disease 100%

Source: ANAM website; http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=18#38

6.3 Essential drug list of Morocco

Table 13: Essential drug list of Morocco

Name Common Class Therapeutic CODE Packaging International

Metabolism --Hematology -- Box Of 90 200100103 Acarbose 100Mg Tablet Diabetes --Nutrition Tablets

Box Of 100 Cardiology - Medicines 1120010103 Acenocoumarol 4Mg Tablets Tablets

Analgesics --Antipyretics -- Acetyl Salicylate Lysine DMP93 Box Of 20 Packs Anti- Inflammatory 100Mg Bag

Acetyl Salicylate Lysine Cardiology - Medicines DMP18 Box 30 Packs 160Mg Bag

Analgesics --Antipyretics -- Acetyl Salicylate Lysine 1G Box Of 6 Bottles DMP17 Anti- Inflammatory Injection + Solvent

Analgesics --Antipyretics -- Acetyl Salicylate Lysine DMP89 Box Of 20 Packs Anti- Inflammatory 250Mg Bag

Acetyl Salicylate Lysine Cardiology - Medicines DMP188 Box 30 Packs 300Mg Bag

Box Of 25 Infectious disease DMP19 Aciclovir 200Mg Tablet Tablets

Infectious disease DMP20 Aciclovir 250Mg Injection Box 1 Bottle

Aciclovir 3% Ophthalmic Ophthalmology DMP190 Tube 4.5 Billion Ointment

Dermatology DMP195 Aciclovir 5% Cream Tube 10 G

Analgesics -- Antipyretics -- Acid 500Mg Tablets Box Of 1000 1000010103 Anti- Inflammatory Acetylsalicylic Tablets

Alendronique Acid 70Mg Rheumatology 1010070103 Box Of 4 Tablets Tablets

Dermatology 2010000201 Fusidic Acid 2% Ointment Or Tube 15 G

Name Common Class Therapeutic CODE Packaging International

Cream

Box Of 10 Infectious disease 4000250103 Fusidic Acid 250Mg Tablet Tablets

Anesthesia - Resuscitation 100010201 Adrenaline Injection 0.25Mg Box 100 Bulbs

Anesthesia - Resuscitation DMP1 Adrenaline Injection 0,50Mg Box 100 Bulbs

Anesthesia - Resuscitation 100020201 Adrenaline Injection 1Mg Box 100 Bulbs

Albendazole 4% Oral Infectious disease 440210106 Bottle 10Ml Suspension

Infectious disease 440200103 Albendazole 400Mg Tablet Box 1 Tablet

Box Of 100 Rheumatology 1020010103 Allopurinol 100Mg Tablet Tablets

Box Of 28 Rheumatology 1020030103 Allopurinol 300Mg Tablet Tablets

Pneumology 120300506 Ambroxol 0.3% Syrup Bottle 150Ml

Amidotrizoate De Sodium And Bottle 250Ml + Products Contrast DMP21 De Meglumine Infusion 30% Injection

Amidotrizoate De Sodium And Bottle 50Ml + Products Contrast DMP106 De Meglumine Infusion 76% Injection

Box + 1 Vial Infectious disease DMP23 Amikacin 250Mg Injection Solvent

Box + 1 Vial Infectious disease DMP3 Amikacin 500Mg Injection Solvent

Cardiology - Medicines 720040501 Amiodarone 150Mg Injection Box Of 6 Bulbs

Box Of 40 Cardiology - Medicines DMP24 Amiodarone 200Mg Tablet Tablets

Psychiatry - Neurology 1220020103 25Mg Tablets Amitriptyline Box Of 60

Name Common Class Therapeutic CODE Packaging International

Tablets

Psychiatry - Neurology DMP84 Amitriptyline 4% Sol Oral Bottle 20Ml

Box Of 28 Cardiology - Medicines 780051003 10Mg Tablets Amlodipine Tablets

Box Of 28 Cardiology - Medicines 780050103 Amlodipine 5Mg Tablet Tablets

Amoxicillin 125Mg + Acid Infectious disease 4100125105 Clavulanic Powder To Bottle 60Ml Suspension Oral

Amoxicillin 125Mg Powder Box Of 10 Infectious disease 410010105 To Suspension Oral Bottles 60Ml

Amoxicillin 1G + Acid Box Of 10 Infectious disease DMP140 Clavulanic Injection Bottles

Amoxicillin + 1G Clavulanic Infectious disease 410010001 Box 14 Packs Acid Bag

Box Of 24 Infectious disease 410010003 Amoxicillin 1G Tablets Tablets

Infectious disease Amoxicillin 1G Injection Box 1 Bulb

Amoxicillin 250Mg + Acid Box 1 Bottle Infectious disease 410720501 Clavulanic Powder To 60Ml Suspension Oral

Amoxicillin 250Mg Powder Box Of 10 Infectious disease 410030105 To Suspension Oral Bottles 60Ml

Amoxicillin 500Mg + Acid Box Of 24 Infectious disease DMP25 Clavulanic Tablets Tablets

Amoxicillin 500Mg + Acid Infectious disease 4100500501 Box 1 Bottle Clavulanic Injection

Infectious disease 410040103 Amoxicillin 500Mg Tablet Or Box De 24

Name Common Class Therapeutic CODE Packaging International

Capsule Tablets Or Capsules

Amphotericin B 10% Oral Infectious disease DMP107 Bottle 40Ml Suspension

Amphotericin B Injection Infectious disease 450050501 Bottle 15Ml 50Mg

Box Of 50 Infectious disease 410050505 Ampicillin 1G Injection Bottles + Solvent

Box Of 50 Infectious disease 410060505 Ampicillin 250Mg Injection Bottles + Solvent

Box Of 50 Infectious disease 410070505 Ampicillin 500Mg Injection Bottles + Solvent

Antitussive Central Syrup Adult To Base De Box Of 25 Pneumology 820010106 Codeine, Codethylene, Bottles 125Ml Pholcodine Or

Box Of 28 Cardiology - Medicines DMP101 Atenolol 100Mg Tablet Tablets

Anesthesia - Resuscitation 100060201 Atracurium Injection 50Mg Box Of 10 Bulbs

Anesthesia - Resuscitation 100060501 Atracurium Injection 25Mg Box Of 10 Bulbs

Anesthesia - Resuscitation 640010601 Atropine 0.25Mg Injection Box 100 Bulbs

Anesthesia - Resuscitation 640050601 Atropine 0,50Mg Injection Box 100 Bulbs

Anesthesia - Resuscitation 640070601 Atropine 1Mg Injection Box 100 Bulbs

Aerosol Beclomethasone Pneumology DMP26 Bottle 200 Doses 50Μg

Benzathine Benzylpenicillin Box Of 50 Infectious disease 410100505 0,6MIU Injection Bottles + Solvent

Infectious disease 410080505 Benzathine Benzylpenicillin Box Of 50

Name Common Class Therapeutic CODE Packaging International

1,2MIU Injection Bottles + Solvent

Benzoate De Benzyl 10% + Box Of 25 Dermatology 440011207 Sulfiram 2% Solution Skin Bottles 150Ml

Benzylpenicillin 1MIU Box Of 50 Infectious disease 410290505 Injection Bottles + Solvent

Benzylpenicillin 5MIU Box Of 6 Bottles Infectious disease 410280505 Injection + Solvent

Benzylpenicillin Procaine Box Of 50 Infectious disease 410270305 1MIU Injection Bottles + Solvent

Analgesics --Antipyretics -- DMP27 Betamethasone 4Mg Injection Box 3 Bulbs Anti- Inflammatory

Betamethasone 8Mg Injection Analgesics --Antipyretics -- DMP28 With Syringe And Needle Box 1 Bulb Anti- Inflammatory Sterile

Box Of 20 Dermatology 2300011215 Biogaze Dressing Compresses Compresses

Box Of 28 Cardiology - Medicines 820010103 10Mg Tablets Bisoprolol Tablets

Metabolism --Hematology -- Box Of 30 200025103 Bromocriptine 2.5 Mg Tablets Diabetes --Nutrition Tablets

N-Butyl Bromide 10Mg Box Of 40 Anesthesia - Resuscitation 640010501 Tablets Of Hyoscine Tablets

Bromide N-Butyl Hyoscine Box Of 6 Anesthesia - Resuscitation 640010105 10Mg Suppositories Suppositories

N-Butyl Bromide For Injection Anesthesia - Resuscitation 640020501 Box Of 50 Bulbs 20Mg Hyoscine

Anesthesia - Resuscitation 210011107 Bupivacaine 0.25% Injection Bottle 20Ml

Anesthesia - Resuscitation 210051107 Bupivacaine 0.50% Injection Bottle 20Ml

Name Common Class Therapeutic CODE Packaging International

Buprenorphine 0.3Mg Anesthesia - Resuscitation 260011105 De10 Bulbs Box Injection

Metabolism --Hematology -- 20005103 Cabergoline 0.5 Mg Tablets Box 8 Tablets Diabetes --Nutrition

Metabolism --Hematology -- Calcium Tablets Effervescent Box Of 30 2100010103 Diabetes --Nutrition 1G Tablets

Metabolism --Hematology -- Calcium 500Mg + Vitamin D3 Box Of 30 2100500103 Diabetes --Nutrition 400 IU Tablets Tablets

Metabolism --Hematology -- 2100010501 Calcium Injection 87Mg Box 5 Bulbs Diabetes --Nutrition

Box Of 30 Cardiology - Medicines 820020103 25Mg Tablets Captopril Tablets

Box Of 30 Cardiology - Medicines DMP120 50Mg Tablets Captopril Tablets

Box Of 50 Psychiatry - Neurology 1240010103 Carbamazepine 200Mg Tablet Tablets

Box Of 30 Psychiatry - Neurology 1240120103 Carbamazepine 400Mg Tablet Tablets

Metabolism --Hematology -- Box Of 50 960010103 Carbimazole 5Mg Tablet Diabetes --Nutrition Tablets

Pneumology DMP6 Carbocysteine 5% Syrup Bottle 125Ml

Box Of 30 Cardiology - Medicines 84000103 Carvedilol 6.25Mg Tablets Tablets

Box + 1 Vial Infectious disease DMP31 Cefalotin 1G Injection Solvent

Cefixime 100Mg Powder To Box 1 Bottle Infectious disease 401100105 Suspension Oral 40Ml

Infectious disease 401040105 Cefixime 40Mg Powder To Box 1 Bottle

Name Common Class Therapeutic CODE Packaging International

Suspension Oral 40Ml

Infectious disease 40110005 Ceftazidime 1G Injection Box 1 Bottle

Box + 1 Vial Infectious disease DMP32 Ceftriaxone 1G Injection Solvent

Box + 1 Vial Infectious disease DMP33 Ceftriaxone 250Mg Injection Solvent

Box Of 20 Infectious disease DMP34 Ceftriaxone 500Mg Injection Bottles + Solvent

Box Of 15 Allergology 300010201 10Mg Tablets Cetirizine Tablets

Cetirizine 1Mg / Ml Oral Allergology 300010101 Bottle 60Ml Suspension

Box De 30 Coal Assets Or Plant Tablets Gastroenterology 600100001 Tablets Or Or Capsules Capsules

Box Of 50 Psychiatry - Neurology 1210020103 Chlorpromazine 100Mg Tablet Tablets

Box Of 50 Psychiatry - Neurology 1210160103 25Mg Tablets Chlorpromazine Tablets

Chlorpromazine Injection Psychiatry - Neurology 1210011001 Box 5 Bulbs 25Mg

Chlortetracycline 1% Box Of 50 Tubes Ophthalmology 1310031619 Ophthalmic Ointment 5 G

Chlortetracycline 3% Dermatology 1810011219 25 Tubes 15 G Ointment Skin

Potassium Chloride Injection Cardiology - Medicines DMP39 Box 100 Bulbs 10%

Cardiology - Medicines DMP141 Potassium Chloride Capsule Box Of 40

Name Common Class Therapeutic CODE Packaging International

600Mg Capsules

Infectious disease DMP1420 200Mg Ciprofloxacin Injection Bottle 100Ml

Box Of 10 Infectious disease DMP142 Ciprofloxacin Tablets 500Mg Tablets

Cisatracurium 10Mg / 5Ml Anesthesia - Resuscitation 100080103 Box 5 Bulbs Injection

Box Of 30 Psychiatry - Neurology 1220070103 25Mg Tablets Clomipramine Tablets

Psychiatry - Neurology 1220061001 Clomipramine Injection 25Mg Box Of 10 Bulbs

Box Of 40 Psychiatry - Neurology DMP40 Clonazepam 2Mg Tablet Tablets

Clonidine 0.15Mg / Ml Cardiology - Medicines 730040501 Box Of 30 Bulbs Injection

Box Of 20 Cardiology - Medicines 730040105 Clonidine 0.15Mg Tablets Tablets

Box Of 28 Cardiology - Medicines 7300750103 Clopidogrel Tablets 75Mg Tablets

Box Of 40 Rheumatology 1020020103 Colchicine Tablets 1Mg Tablets

Box 25 Tubes Dermatology 1890061202 Collargol 5% Ointment 5G

Cyclopentolate 0.5% Eye Box Of 10 Ophthalmology 1340041609 Drops Bottles 0.5Ml

Oncology --Hormone Therapy - Cyclophosphamide 200Mg Box Of 10 101004201 -Immunology Injection Bottles

Oncology --Hormone Therapy - Cyclophosphamide 500Mg 101004501 Box 1 Bottle -Immunology Injection

Analgesics --Antipyretics -- DMP41 Dexamethasone Tablets 0.5Mg Box Of 40

Name Common Class Therapeutic CODE Packaging International

Anti- Inflammatory Tablets

Analgesics --Antipyretics -- DMP143 Dexamethasone Injection 5Mg Box 3 Bulbs Anti- Inflammatory

Dexchlorpheniramine 2Mg Box Of 30 Allergology 300020103 Tablet Tablets

Psychiatry - Neurology 1230020501 Diazepam Injection 10Mg Box Of 50 Bulbs

Box Of 40 Psychiatry - Neurology 1230040103 Diazepam 5Mg Tablet Tablets

Analgesics --Antipyretics -- Diclofenac 25Mg Box 10 DMP47 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Diclofenac 100Mg Box 10 1000141418 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Diclofenac 12.5Mg Box 10 DMP46 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Box Of 100 DMP9 50Mg Tablets Diclofenac Anti- Inflammatory Tablets

Analgesics --Antipyretics -- 1000141475 Diclofenac Injection 75Mg Box 2 Bulbs Anti- Inflammatory

Box Of 30 Cardiology - Medicines 740030103 Digoxin 0.25 Mg Tablets Tablets

Cardiology - Medicines DMP48 Digoxin 5% Oral Solution Bottle 60Ml

Box Of 40 Cardiology - Medicines 730030105 25Mg Tablets Dihydralazine Tablets

Box De 30 Diltiazem 90Mg Tablets Or Cardiology - Medicines 750010901 Tablets Or Capsules Capsules

Dinitrate Isosorbide 20Mg Box Of 60 Cardiology - Medicines 710020803 Capsules Capsules

Name Common Class Therapeutic CODE Packaging International

Dinitrate Isosorbide 10Mg Box Of 60 Cardiology - Medicines 710011803 Tablets Tablets

Dinitrate Isosorbide 5Mg Box Of 30 Cardiology - Medicines 710040103 Tablet Tablets

Gastroenterology 6013000301 Diosmectite 3G Bag Box 60 Packs

Box Of 30 Cardiology - Medicines 750030103 Diosmin 300Mg Tablet Tablets

Anesthesia - Resuscitation 100130201 Dobutamine 250Mg Injection Box 1 Bottle

Domperidone 0.1% Oral Gastroenterology DMP49 Bottle 200Ml Suspension

Box Of 20 Gastroenterology DMP50 10Mg Tablets Domperidone Tablets

Anesthesia - Resuscitation 100100201 Dopamine 200Mg Injection Box Of 20 Bulbs

Anesthesia - Resuscitation 100030201 Dopamine Injection 50Mg Box Of 50 Bulbs

Oncology --Hormone Therapy - 1010030205 Doxorubicin Injection 50Mg Box 1 Bottle -Immunology

Box Of 10 Infectious disease 410700103 Doxycycline 200Mg Tablet Tablets

Water For Injection Box 100 Bulbs Solvents 2300040201 Preparation 5Ml

Econazole 1% Ointment Or Dermatology DMP510 Tube 30 G Cream

Econazole 150Mg Ova Gynecology - Obstetrics DMP51 Box 3 Ova Gynaecological

Box Of 28 Cardiology - Medicines 750050201 20Mg Tablets Enalapril Tablets

Box Of 28 Cardiology - Medicines 750050005 Enalapril 5Mg Tablet Tablets

Name Common Class Therapeutic CODE Packaging International

Carton Of 15 Eosine Disodium 2% Solution Dermatology 1840061207 Bottles Of 1 Skin Litre

Anesthesia - Resuscitation 100150202 Ephedrine 3% Injection Box Of 10 Bulbs

Metabolism --Hematology -- Epoetin Alfa 2000Ui / Ml Box Of 10 300020510 Diabetes --Nutrition Injection Bottles

Metabolism --Hematology -- Epoetin Alfa 2000Ui / Ml Box Of 6 Needle 3000205065 Diabetes --Nutrition Injection 0.5Ml

Metabolism --Hematology -- Epoetin Alfa 4000Ui / Ml Box Of 6 Needle 3000405065 Diabetes --Nutrition Injection 0.5Ml

Metabolism --Hematology -- Epoetin Alfa 10000Ui / Ml Box Of 6 Needle 300010504 Diabetes --Nutrition Injection 0.4Ml

Metabolism --Hematology -- 300010506 Epoetin Beta 1000Ui Injection Box Of 6 Needle Diabetes --Nutrition

Metabolism --Hematology -- 3000205063 Epoetin Beta 2000Ui Injection Box Of 6 Needle Diabetes --Nutrition

Metabolism --Hematology -- 3000305063 Epoetin Beta 3000Ui Injection Box Of 6 Needle Diabetes --Nutrition

Metabolism --Hematology -- 3000505063 Epoetin Beta 5000Ui Injection Box Of 6 Needle Diabetes --Nutrition

Metabolism --Hematology -- Epoetin Beta 10000Ui 3000105063 Box Of 6 Needle Diabetes --Nutrition Injection

Erythromycin 125Mg Pellet Infectious disease 410170116 Box 12 Packs To Suspension Oral

Box Of 100 Infectious disease 410180103 Erythromycin Tablets 500Mg Tablets

Box Of 20 Cardiology - Medicines DMP540 Etamsylate 250Mg Tablet Tablets

Name Common Class Therapeutic CODE Packaging International

Cardiology - Medicines DMP54 Etamsylate 250Mg Injection Box Of 6 Bulbs

Box Of 20 Cardiology - Medicines DMP55 Etamsylate 500Mg Tablet Tablets

Anesthesia - Resuscitation 100180301 Etomidate 2Mg / Ml Injection Box 5 Bulbs

Box Of 30 Cardiology - Medicines 7500200103 Fenofibrate 200Mg Capsules Capsules

Fentanyl 100 Micrograms / 2 Anesthesia - Resuscitation DMP85 Box 5 Bulbs Ml Injectable

Fentanyl 500Μg / 10 Ml Anesthesia - Resuscitation DMP86 Box Of 10 Bulbs Injectable

Metabolism --Hematology -- 140010106 Iron Pediatric Syrup Bottle 150Ml Diabetes --Nutrition

Metabolism --Hematology -- 140030501 Filgrastim 300Μg Injection Box 1 Syringe Diabetes --Nutrition

Metabolism --Hematology -- 1400480501 Filgrastim 480Μg Injection Box 1 Syringe Diabetes --Nutrition

Flucloxacillin 125Mg Oral Box Of 10 Infectious disease 410670105 Suspension Bottles 60Ml

Box Of 10 Infectious disease 410510501 Flucloxacillin 1G Injection Bottles + Solvent

Box Of 10 Infectious disease 410660501 Flucloxacillin 250Mg Injection Bottles + Solvent

Flucloxacillin 250Mg Oral Box Of 10 Infectious disease 410680105 Suspension Bottles 60Ml

Box Of 12 Infectious disease 410680103 Flucloxacillin 500Mg Capsule Capsules

Box Of 10 Infectious disease 410500501 Flucloxacillin 500Mg Injection Bottles + Solvent

Name Common Class Therapeutic CODE Packaging International

Box Of 4 Infectious disease 411150103 Fluconazole 150Mg Capsules Capsules

Fluconazole 2Mg / Ml Infectious disease 41120005 Bottle 100Ml Injection

Infectious disease 411050103 Fluconazole 50Mg Capsules Box 7 Capsules

Fluorescein 10% Sodium Ophthalmology 1340071609 Box Of 10 Bulbs Injection

Box Of 20 Psychiatry - Neurology 1260020103 Fluoxetine 20Mg Capsules Capsules

Fluphenazine Decanoate Psychiatry - Neurology 1210050301 Box Of 50 Bulbs Injection 25Mg

Fluticasone + Salmeterol 100 / 60 Single Dose Pneumology 1200100506 50Μg Inhalation Containers

Fluticasone + Salmeterol 250 / 60 Single Dose Pneumology 1200250506 50Μg Inhalation Containers

Metabolism --Hematology -- Fumarate Ferrous 200Mg Box Of 100 1130020103 Diabetes --Nutrition Tablet Tablets

Cardiology - Medicines 770020501 Furosemide Injection 20Mg Box Of 25 Bulbs

Cardiology - Medicines 7700250501 Furosemide 250Mg Injection Box 5 Bulbs

Box Of 100 Cardiology - Medicines 770030103 40Mg Tablets Furosemide Tablets

Box Of 50 Cardiology - Medicines 7700500103 Furosemide 500Mg Tablet Tablets

Box Of 10 Ophthalmology 1310071609 Gentamicin 0.3% Eye Drops Bottles 5Ml

Infectious disease 410551205 Gentamicin 120Mg Injection Box Of 6 Bulbs

Infectious disease 410550501 Gentamicin 160Mg Injection Box Of 25 Bulbs

Infectious disease 410190501 Gentamicin Injection 20Mg Box Of 25 Bulbs

Name Common Class Therapeutic CODE Packaging International

Infectious disease 410200501 Gentamicin Injection 40Mg Box Of 25 Bulbs

Infectious disease 410210501 Gentamicin Injection 80Mg Box Of 25 Bulbs

Metabolism --Hematology -- Box Of 100 920010103 Glibenclamide 5Mg Tablet Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 60 920030103 30Mg Tablets Gliclazide Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 60 920060103 80Mg Tablets Gliclazide Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 30 1500100103 Glimepiride Tablets 1Mg Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 30 1500200103 Glimepiride 2Mg Tablet Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 30 1500300103 Glimepiride 3Mg Tablets Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 30 1500400103 Glimepiride 4Mg Tablets Diabetes --Nutrition Tablets

Metabolism --Hematology -- 1700100501 Glucagon 1Mg Injection Box 1 Bottle Diabetes --Nutrition

Box Of 100 Infectious disease 450020103 Griseofulvin 125Mg Tablet Tablets

Box Of 30 Infectious disease DMP57 Griseofulvin 250Mg Tablet Tablets

Dermatology DMP56 Griseofulvin 5% Ointment Tube 15 G

Box Of 30 Infectious disease 450030103 Griseofulvin 500Mg Tablet Tablets

Psychiatry - Neurology 1210080901 Haloperidol 5Mg Injection Box Of 50 Bulbs

Box Of 25 Psychiatry - Neurology 1210070109 Haloperidol 0.2% Oral Sol Bottles 15Ml

Name Common Class Therapeutic CODE Packaging International

Halothane Suspension 250Mg Anesthesia - Resuscitation 220031310 Bottle 250Ml Inhalation

Box De 10 Heparin Sodium Injection 25 Cardiology - Medicines DMP108 Bottles Or 10 000Ui Bulbs

Heparin To Bas Weight Cardiology - Medicines DMP1009 Molecular 2000 To3000Ui Box 2 Needle Anti-Xa, Injection

Heparin To Bas Weight Cardiology - Medicines DMP870 Molecular 3500 To4500Ui Box 2 Needle Anti-Xa, Injection

Heparin To Bas Weight Cardiology - Medicines DMP1008 Molecular 5000 To6000Ui Box 2 Needle Anti-Xa, Injection

Carton Of 15 Other 650010107 Paraffin Oil Bottles Of 1 Litre

Hydrochlorothiazide 25Mg Box Of 20 Cardiology - Medicines 770070103D Tablets Tablets

Hydrochlorothiazide 50Mg + Box Of 28 Cardiology - Medicines 770070103 Amiloride 5Mg Tablets Tablets

Analgesics --Antipyretics -- Hydrocortisone 100Mg 910010508 Box Of 10 Bulbs Anti- Inflammatory Injection

Analgesics --Antipyretics -- Box Of 25 910080103 10Mg Tablets Hydrocortisone Anti- Inflammatory Tablets

Hydroxide Aluminum And De Gastroenterology 610010101 Bottle 250Ml Magnesium Suspension Oral

Anesthesia - Resuscitation 300060501 Hydroxyzine 100Mg Injection Box Of 6 Bulbs

Analgesics --Antipyretics -- DMP122 Ibuprofen 100Mg / 5Ml Syrup Bottle 150Ml

Name Common Class Therapeutic CODE Packaging International

Anti- Inflammatory

Imipenem 250Mg + Cilastatin Box Of 10 Infectious disease 4052502505 250Mg Injection Bottles

Imipenem 500Mg + Cilastatin Infectious disease 4055005005 Box 1 Bottle 500Mg Injection

Box Of 100 Psychiatry - Neurology DMP58 25Mg Tablets Imipramine Tablets

Box Of 30 Cardiology - Medicines 78008001 Indapamide 1.5 Mg Tablets Lp Tablets

Box Of 30 Cardiology - Medicines 78008002 Indapamide 2.5 Mg Tablets Tablets

Box Of 10 Ophthalmology 1340051609 Indomethacin 0.1% Eye Drops Bottles

Analgesics --Antipyretics -- Indomethacin 100Mg Box Of 20 1000014118 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Box Of 30 1000050103 Indomethacin 25Mg Capsules Anti- Inflammatory Capsules

Anesthesia - Resuscitation 100090201 Isoprenaline 0.2Mg Injection Box Of 50 Bulbs

Josamycin 250Mg Powder For Box D1 'Bottle Infectious disease 405250105 Oral Susp 60Ml

Josamycin 500Mg Powder For Box 1 Bottle Infectious disease 405500105 Oral Susp 60Ml

Anesthesia - Resuscitation 400010101 Ketamine 10Mg / Ml Injection Box Of 25 Bulbs

Anesthesia - Resuscitation 400050101 Ketamine 50Mg / Ml Injection Box Of 25 Bulbs

Analgesics --Antipyretics -- 1000100501 Ketoprofen 100Mg Injection Box Of 60 Bulbs Anti- Inflammatory

Analgesics --Antipyretics -- Box Of 30 1000200501 Ketoprofen 100Mg Tablet Anti- Inflammatory Tablets

Name Common Class Therapeutic CODE Packaging International

Lactate De Sodium Chloride De Sodium Chloride De Carton Of 12 Anesthesia - Resuscitation 300300301 Potassium, Chloride De Bottles 500Ml Calcium

Gastroenterology 600500501 Lactulose 50% Oral Solution Bottle 200Ml

Metabolism --Hematology -- Lenograstim 33.6 MIU 1800336501 Box 5 Bottles Diabetes --Nutrition Injection

Metabolism --Hematology -- Lenograstim 34 MIUMIU 1800340501 Box 1 Bottle Diabetes --Nutrition Injection

Levomepromazine 100Mg Box Of 100 Psychiatry - Neurology 1210100103 Tablet Tablets

25Mg Tablets Box Of 100 Psychiatry - Neurology 1210120103 Levomepromazine Tablets

Levomepromazine Injection Psychiatry - Neurology 1210110301 Box 5 Bulbs 25Mg

Metabolism --Hematology -- Levothyroxine Sodium 100 Box Of 50 960030103 Diabetes --Nutrition Micrograms Tablets Scored Tablets

Metabolism --Hematology -- Levothyroxine Sodium Tablets Box Of 28 9600500103 Diabetes --Nutrition 50Μg Tablets

Box Of 10 Anesthesia - Resuscitation 210060407 Lidocaine 1% Injection Bottles

Lidocaine 2% + Adrenaline Box Of 10 Anesthesia - Resuscitation 210020607 Injection Bottles

Box Of 10 Anesthesia - Resuscitation 210030607 Lidocaine 2% Injection Bottles

Anesthesia - Resuscitation 210040701 Lidocaine 5% + Naphazoline Bottle 24Ml

Anesthesia - Resuscitation 210040407 Lidocaine 5% Contact Bottle 24Ml

Psychiatry - Neurology 1270250103 Lithium 250Mg Tablet Box Of 100

Name Common Class Therapeutic CODE Packaging International

Tablets

Box Of 60 Psychiatry - Neurology 1270400103 Lithium 400Mg Tablet Tablets

Box Of 20 Gastroenterology 6004002001 Loperamide 2Mg Capsule Capsules

Box Of 15 Allergology DMP123 10Mg Tablets Loratadine Tablets

Allergology DMP124 Loratadine 5Mg / 5Ml Syrup Bottle 60Ml

Cardiology - Medicines 730060503 50Mg Tablets Losartan Box 30 Tablets

Metabolism --Hematology -- DMP129 Magnesium Sulfate Injection Box 5 Bulbs Diabetes --Nutrition

Box Of 12 Cardiology - Medicines 2220040407 10% Mannitol Injection Bottles 500Ml

Cardiology - Medicines 2220040807 20% Mannitol Injection Pocket 500Ml

Box 30 Scored Anesthesia - Resuscitation 640200103 Mebeverine 200Mg Tablet Tablets

Oncology --Hormone Therapy - Box Of 50 1010050201 Melphalan 2Mg Tablet -Immunology Tablets

Psychiatry - Neurology 1230050301 Meprobamate 400Mg Injection Box Of 10 Bulbs

Mequitazine 0.06 G / Syrup Allergology 300040006 Bottle 120Ml 120Ml

Mesalazine 1% Rectal Gastroenterology 600600501 Box 5 Bottles Suspension

Box 15 Gastroenterology 6006001003 Mesalazine 1G Suppositories Suppositories

Box Of 100 Gastroenterology 6006050103 Mesalazine 500Mg Tablet Tablets

Oncology --Hormone Therapy - 1010060401 Mesna 400Mg Injection Box Of 15 Bulbs

Name Common Class Therapeutic CODE Packaging International

-Immunology

Metabolism --Hematology -- Box Of 30 9200510103 Metformin 1000Mg Tablets Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 50 DMP59 Metformin 500Mg Tablet Diabetes --Nutrition Tablets

Metabolism --Hematology -- Box Of 60 920050103 Metformin 850Mg Tablets Diabetes --Nutrition Tablets

Oncology --Hormone Therapy - 1010070201 Methotrexate Injection 25Mg Box 1 Bottle -Immunology

Box Of 30 Cardiology - Medicines 730020103 Methyldopa 250Mg Tablet Tablets

Methylergometrine 0.2Mg Gynecology - Obstetrics 1630010501 Box Of 50 Bulbs Injection

Analgesics --Antipyretics -- Methylprednisolone 120Mg Box Of 10 910050201 Anti- Inflammatory Injection Bottles

Analgesics --Antipyretics -- Methylprednisolone Injection Box Of 10 910040201 Anti- Inflammatory 40Mg Bottles

Analgesics --Antipyretics -- Methylprednisolone 500Mg Box Of 10 910050501 Anti- Inflammatory Injection Bottles

Box Of 500 Gastroenterology 620020103 10Mg Tablets Metoclopramide Tablets

Metoclopramide Injection Gastroenterology 620010501 Box Of 50 Bulbs 10Mg

Metoclopramide 20Mg Box 10 Gastroenterology 620020502 Suppositories Suppositories

Metoclopramide 260Mg / Sol Box 1 Flaconde Gastroenterology 620030109 100Ml Oral 60Ml

Gastroenterology 620016503 Metoclopramide Delay 16Mg Box Of 30

Name Common Class Therapeutic CODE Packaging International

Capsule Capsules

Metopimazine 0.4% Oral Gastroenterology 620004504 Bottle 30Ml Solution

Metopimazine 10Mg / Ml Gastroenterology 6007010501 Box Of 10 Bulbs Injection

Metopimazine 5Mg Box 10 Gastroenterology 6007050003 Suppositories Suppositories

Box Of 100 Infectious disease 440080103 Metronidazole 250Mg Tablet Tablets

Box Of 25 Infectious disease 440070106 4% Metronidazole Syrup Bottles 120Ml

Box Of 100 Infectious disease 440280103 Metronidazole 500Mg Tablet Tablets

Metronidazole 500Mg Infectious disease DMP60 Pocket 100Ml Injection

Gynecology - Obstetrics 440091514 Metronidazole 500Mg Ova Box 50 Ova

Midazolam 5Mg / 5Ml Box Of 6 Bulbs Psychiatry - Neurology 220100201 Injection 5Ml

Box Of 14 Anesthesia - Resuscitation 1010030709 Morphine 100Mg Tablets Lp Tablets

Box Of 14 Anesthesia - Resuscitation 1010030701 10Mg Tablets Morphine Lp Tablets

Box Of 14 Anesthesia - Resuscitation 1010030702 20Mg Tablets Morphine Lp Tablets

Box Of 14 Anesthesia - Resuscitation 1010030703 30Mg Tablets Morphine Lp Tablets

Box Of 14 Anesthesia - Resuscitation 1010030706 60Mg Tablets Morphine Lp Tablets

Name Common Class Therapeutic CODE Packaging International

Morphine Hydrochloride Anesthesia - Resuscitation 1010030601 Box 100 Bulbs Injection 10Mg

Analgesics --Antipyretics -- 810020201 Nefopam Injection 20Mg Box Of 15 Bulbs Anti- Inflammatory

Anesthesia - Resuscitation 100120201 Neostigmine 0.5Mg Injection Box Of 60 Bulbs

Cardiology - Medicines 710080501 Nicardipine Injection 10Mg Box Of 10 Bulbs

Box Of 60 Cardiology - Medicines 710080105 Nicardipine 50Mg Capsules Capsules

Box Of 50 Cardiology - Medicines 730060103 20Mg Tablet Nifedipine Tablets

Box Of 30 Cardiology - Medicines 730060303 30Mg Tablets Nifedipine Tablets

Box Of 30 Infectious disease DMP64 Nifuroxazide 100Mg Capsule Capsules

Box Of 30 Infectious disease DMP65 Nifuroxazide 200Mg Capsule Capsules

Infectious disease DMP66 Nifuroxazide Oral Suspension Bottle 90Ml

Box Of 50 Infectious disease 455100103 Nitroxoline 100Mg Tablet Tablets

Nystatin 000Ui 100 / Ml Oral Bottle Of 24 Infectious disease 4500100106 Suspension Doses

Box Of 28 Gastroenterology 6100410103 10Mg Capsule Omeprazole Capsules

Box Of 28 Gastroenterology 610040103 20Mg Capsule Omeprazole Capsules

Gastroenterology 6100440501 Omeprazole Injection 40Mg Box 5 Bottles

Ondansetron 4Mg / 2Ml Gastroenterology 6008040005 Box 5 Bulbs Injection

Name Common Class Therapeutic CODE Packaging International

Oxytetracycline + Ophthalmology DMP68 Dexamethasone Ointment Box 12 Unidoses Ophthalmic

Gynecology - Obstetrics 1630020401 Oxytocin 5 IU Injection Box 3 Bulbs

Pancuronium 4Mg Bromide Anesthesia - Resuscitation 220010201 Box Of 10 Bulbs Injection

Analgesics --Antipyretics -- Paracetamol 100Mg Box 100 DMP110 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Paracetamol 125Mg Box 100 1000021418 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- DMP125 Paracetamol 150Mg Bags Box 12 Packs Anti- Inflammatory

Analgesics --Antipyretics -- Paracetamol 150Mg Box 100 DMP116 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Paracetamol 170Mg Box 100 100002170 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Box Of 12 DMP126 Paracetamol 1G Injection Anti- Inflammatory Bottles

Analgesics --Antipyretics -- Box Of 10 1000090103 Paracetamol 1G Tablets Anti- Inflammatory Tablets

Analgesics --Antipyretics -- DMP112 Paracetamol 200Mg Bags Box 12 Packs Anti- Inflammatory

Analgesics --Antipyretics -- Paracetamol 200Mg Box 100 DMP111 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Paracetamol 250Mg Box 100 1000031418 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- 1000010418 Paracetamol Syrup 3% Bottle 90Ml Anti- Inflammatory

Name Common Class Therapeutic CODE Packaging International

Analgesics --Antipyretics -- DMP117 Paracetamol 300Mg Bags Box 12 Packs Anti- Inflammatory

Analgesics --Antipyretics -- Paracetamol 300Mg Box 100 DMP118 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Paracetamol 350Mg Box 100 1000035018 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Paracetamol 400Mg + Codeine Box Of 16 1000062018 Anti- Inflammatory 20Mg Tablets Tablets

Paracetamol 400Mg + Analgesics --Antipyretics -- Box Of 18 1000063018 Dextropropoxyphene Anti- Inflammatory Capsules 30Mg Capsules

Analgesics --Antipyretics -- Box Of 100 1000070103 Paracetamol 500Mg Tablet Anti- Inflammatory Tablets

Analgesics --Antipyretics -- Box Of 12 1000070301 Paracetamol 500Mg Injection Anti- Inflammatory Bottles 50Ml

Analgesics --Antipyretics -- Paracetamol 500Mg Box 100 1000057003 Anti- Inflammatory Suppositories Suppositories

Analgesics --Antipyretics -- Paracetamol 80Mg Box 100 1000081418 Anti- Inflammatory Suppositories Suppositories

Box Of 80 Psychiatry - Neurology 1240050103 10Mg Tablets Phenobarbital Tablets

Psychiatry - Neurology 1240020501 Phenobarbital 200Mg Injection Box 5 Bulbs

Box Of 50 Psychiatry - Neurology 1240060801 Phenobarbital Injection 40Mg Bottles + Solvent

Box Of 30 Psychiatry - Neurology 1240070103 50Mg Tablets Phenobarbital Tablets

Phenoxymethylpenicillin 0.25 Box Of 25 Infectious disease 410310105 MIU / 5Ml Syrup Bottles 100Ml

Name Common Class Therapeutic CODE Packaging International

Phenoxymethylpenicillin 1 Box Of 12 Infectious disease 410300103 MIUMIU Tablets Tablets

Ophthalmology DMP35 Phenylephrine 10% Eye Drops Bottle 10Ml

Serum Glucose 10% Hypert Cardboard 12 Anesthesia - Resuscitation 2220 500 Ml Pocket Pockets 500Ml

Serum Glucose 15% 500 Ml Carton Of 12 Anesthesia - Resuscitation 2220020407 Bottle Bottles 500Ml

Serum Glucose 30% 125 Ml Carton Of 12 Anesthesia - Resuscitation 2220030407 Bottle Bottles 125Ml

Serum Glucose 5% 250 Ml Carton Of 12 Anesthesia - Resuscitation 2220120407 Bottle Bottles 250Ml

Serum Glucose 5% 250 Ml Cardboard 12 Anesthesia - Resuscitation 2220120407 Pocket Pockets 250Ml

Box Of 60 Cardiology - Medicines 790020103 Simvastatin 20Mg Tablets Tablets

Box Of 60 Cardiology - Medicines 790040103 Simvastatin 40Mg Tablets Tablets

Sodium Bicarbonate 1.4% 250 Carton Of 12 Anesthesia - Resuscitation 2220060407 Ml Bottle Bottles 250Ml

Sodium Chloride 0.9% 500 Ml Carton Of 12 Anesthesia - Resuscitation 2220100407 Bottle Bottles 500Ml

Sodium Chloride 0.9% 500 Ml Cardboard 12 Anesthesia - Resuscitation 2220100407 Pocket Pockets 500Ml

Sodium Chloride Injection Anesthesia - Resuscitation 222018 Box 100 Bulbs 10%

Solution Antiseptic To Gynecology - Obstetrics DMP75F Application Local In Bottle 250Ml Gynecology

Name Common Class Therapeutic CODE Packaging International

Solution De Filling Vascular Pocket Or Bottle Anesthesia - Resuscitation DMP121 To Base 500Ml De Gelatin Or Dextran Or

Infectious disease 410620105 Spiramycin 0.375 MIU Syrup Bottle 150Ml

Spiramycin 0.75 MIU Tablets Box De 20 Infectious disease DMP114 Or Bag Tablets Or Bags

Spiramycin 1.5 MIU + Box Of 15 Infectious disease 410390103 Metronidazole 250Mg Tablets Tablets

Spiramycin 1.5 MIU Tablets Box De 16 Infectious disease DMP115 Or Bag Tablets Or Bags

Box Of 10 Infectious disease 4103000103 Spiramycin 3 MIU Tablets Tablets

Spironolactone 25Mg + Box Of 20 Cardiology - Medicines 7700602501 Altizide 15Mg Tablets Tablets

Box Of 20 Cardiology - Medicines 770060501 50Mg Tablets Spironolactone Tablets

Streptokinase 1500 000Ui Cardiology - Medicines 100140201 Box 1 Bottle Injection

Anesthesia - Resuscitation 333030201 Sufentanil 250Μg Injection Box Of 10 Bulbs

Anesthesia - Resuscitation 333010201 Sufentanil 50Μg Injection Box 5 Bulbs

Dermatology 1980021701 Sulfadiazine Silver Cream 1% Tube 50 G

Sulfamethoxazole 100Mg + Box Of 200 Infectious disease 410130103 Trimethoprim Tablets 20Mg Tablet

Sulfamethoxazole 4G + Carton Of 10 Infectious disease 410140105 Trimethoprim 800Mg Bottles 100Ml Suspension Oral

Name Common Class Therapeutic CODE Packaging International

Sulfamethoxazole 800Mg + Box Of 20 Infectious disease 410640103 Trimethoprim Tablets 160Mg Tablet

Sulphametoxazole 400Mg + Box Of 200 Infectious disease 410160103 Trimethoprim Tablets 80Mg Tablet

Box Of 100 Gastroenterology DMP77 Sulfasalazine 500Mg Tablet Tablets

Barium Sulfate Sol. Oral Or Products Contrast 2200020105 Bottle 150Ml Rectal

Sulfate De Copper + Sulfate Box Of 25 Tubes Dermatology 1890021202 De Zinc + Oxide De Zinc + 20G Camphor Ointment

Metabolism --Hematology -- Ferrous Sulphate 80Mg Box Of 30 1133080103 Diabetes --Nutrition Tablets Tablets

Box De 10 Analgesics --Antipyretics -- 20Mg Tablets Or Capsules 930020103 Tablets Or Anti- Inflammatory Tenoxicam Capsules

Analgesics --Antipyretics -- Tenoxicam 20Mg Box Of 6 930020301 Anti- Inflammatory Suppositories Suppositories

Metabolism --Hematology -- DMP78 Tetracosactide 1Mg Injection Box 1 Bulb Diabetes --Nutrition

Box Of 100 Infectious disease 410350103 Tetracycline 500Mg Tablet Tablets

Theophylline 300Mg Tablets Box Of 30 Pneumology DMP144 Lp Tablets

Metabolism --Hematology -- Thiamine + Pyridoxine + Box Of 20 2100050103 Diabetes --Nutrition Cyanocobalamin Tablets Tablets

Infectious disease 410360505 Thiamphenicol 750Mg Box Of 8 Bottles

Name Common Class Therapeutic CODE Packaging International

Injection + Solvent

Thiamphenicol 125Mg Powder Infectious disease DMP79 Bottle 60Ml For Oral Susp

Box Of 16 Infectious disease 410540103 Thiamphenicol 250Mg Tablet Tablets

Box Of 16 Infectious disease 410500103 Thiamphenicol 500Mg Tablet Tablets

Thiocolchicoside 4Mg Anesthesia - Resuscitation DMP145 Box Of 6 Bulbs Injection

Thiopental 1G Sodium Box Of 50 Anesthesia - Resuscitation 220070205 Injection Bottles

Tiemonium Simple 20Mg Box 100 Anesthesia - Resuscitation 640101418 Suppositories Suppositories

Tiemonium Single Injection Anesthesia - Resuscitation 640080501 Box Of 10 Bulbs 5Mg

Tiemonium Simple 10Mg / Anesthesia - Resuscitation 640070101 Bottle 150Ml 5Ml Syrup

Ophthalmology 1320031609 Timolol 0.50% Eye Drops Bottle 5Ml

Analgesics --Antipyretics -- Tramadol 100Mg Box 5 960010031 Anti- Inflammatory Suppositories Suppositories

Box De 20 Analgesics --Antipyretics -- Tramadol 50Mg Tablets Or 960050103 Tablets Or Anti- Inflammatory Capsules Capsules

Box Of 20 Psychiatry - Neurology 1250030103 Trihexyphenidyl 5Mg Tablet Tablets

Anesthesia - Resuscitation 710010103 Trimebutine Oral Suspension Bottle 250Ml

Trimebutine 150Mg Tablet Or Box De 30 Anesthesia - Resuscitation 710050101 Capsule Tablets Or

Name Common Class Therapeutic CODE Packaging International

Capsules

Trimetazidine Dihydrochloride Box Of 60 Cardiology - Medicines 790060201 20Mg Tablets Tablets

Nitroglycerin 0.3Mg / Spray Cardiology - Medicines DMP96 Bottle 300 Doses Aerosol

Cardiology - Medicines 710050501 Nitroglycerin Injection 15Mg Box Of 50 Bulbs

Cardiology - Medicines 710050301 Nitroglycerin 3Mg Injection Box Of 50 Bulbs

Box Of 60 Cardiology - Medicines DMP81 Nitroglycerin 6,5Mg Capsule Capsules

Box Of 10 Ophthalmology DMP82 Tropicamide 0.5% Eye Drops Bottles 10Ml

Psychiatry - Neurology DMP83 Valproate Sodium Syrup Bottle 150Ml

Valproate Sodium Tablets Box Of 40 Psychiatry - Neurology 1240100103 200Mg Tablets

Valproate De Sodium 200Mg / Psychiatry - Neurology 1240090107 Bottle 40Ml Ml Solution Oral

Infectious disease 430500501 Vancomycin 500Mg Injection Box 1 Bottle

Other 1890051202 White Vaseline Pack Of 1 Kg

Vecuronium 4Mg Bromide Anesthesia - Resuscitation 220080201 Box Of 10 Bulbs Injection

Oncology --Hormone Therapy - 1010081001 Vincristine 1Mg Injection Box 1 Bottle -Immunology

6.4 Reimbursement of anti-cancer drugs (in MAD)

Table 14: Reimbursements of anti-cancer drugs

CONCENTRATION OF AVASTIN BEVACIZUMAB SOLUTION FOR 1 BOX 1 BOTTLE 3,983.00 3,983.00 3,689.00 3,689.00 INFUSION AT 100 MG INFUSION AT 400 MG AVASTIN BEVACIZUMAB POWDER FOR 1 BOX 1 BOTTLE 13,417.00 13,417.00 13,161.00 13,161.00 SOLUTION INJECTION 15 MG BLUCIN BLEOMYCINE POWDER FOR 1 BOX 1 BOTTLE 215.00 215.00 134.40 134.40 SOLUTION

BLEOMYCINE BLEOMYCINE INJECTION 15 MG 1 BOX 1 BOTTLE 345.00 215.00 229.00 134.40 BELLON

FILM-COATED XELODA CAPECITABINE 1 BOX 60 TABLETS 559.70 559.70 TABLETS 150 MG

FILM-COATED 1 BOX 120 XELODA CAPECITABINE 3,696.00 3,696.00 3,393.00 3,393.00 TABLETS 500 MG TABLETS

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 272.00 272.00 181.00 181.00 DBL INFUSION AT 50 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 272.00 272.00 181.00 181.00 MYLAN INFUSION AT 50 MG

CARBOPLATINE SOLUTION FOR AGUETTANT 50 CARBOPLATINE 1 BOX 1 BOTTLE 467.00 467.00 310.00 310.00 INFUSION AT 50 MG MG

OKA- SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 572.00 572.00 380.00 380.00 CARBOPLATIN INFUSION AT 150 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 663.00 663.00 441.00 441.00 DBL INFUSION AT 150 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 684.00 684.00 454.00 454.00 MYLAN INFUSION AT 150 MG

CARBOPLATINE SOLUTION FOR AGUETTANT 150 CARBOPLATINE 1 BOX 1 BOTTLE 1,096.00 1,096.00 820.00 820.00 INFUSION AT 150 MG MG

OKA- SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 1,175.00 1,175.00 900.00 900.00 CARBOPLATIN INFUSION AT 450 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 1,493.00 1,493.00 1,228.00 1,228.00 DBL INFUSION AT 450 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOX 1 BOTTLE 1,577.00 1,577.00 1,315.00 1,315.00 MYLAN INFUSION AT 450 MG

CARBOPLATINE SOLUTION FOR AGUETTANT 450 CARBOPLATINE 1 BOX 1 BOTTLE 2,713.00 2,713.00 2,381.00 2,381.00 INFUSION AT 50 MG MG

SOLUTION FOR PARAPLATINE CARBOPLATINE 1 BOTTLE 5 ML 835.30 835.30 552.50 552.50 INFUSION AT 450 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOTTLE 15 ML 686.00 686.00 456.00 456.00 COOPER INFUSION AT 150 MG

SOLUTION FOR PARAPLATINE CARBOPLATINE 1 BOTTLE 15 ML 1,871.00 686.00 1,237.70 456.00 INFUSION AT 150 MG

CARBOPLATINE SOLUTION FOR CARBOPLATINE 1 BOTTLE 45 ML 1,553.00 1,553.00 1,289.00 1,289.00 COOPER INFUSION AT 450 MG

SOLUTION FOR PARAPLATINE CARBOPLATINE 1 BOTTLE 45 ML 5,586.80 1,553.00 3,695.70 1,289.00 INFUSION AT 450 MG

POWDER FOR ZAREX CARBOPLATINE SOLUTION 1 BOX 1 BOTTLE 968.00 968.00 687.00 687.00 INJECTION 150 MG POWDER FOR ZAREX CARBOPLATINE SOLUTION 1 BOX 1 BOTTLE 2,289.00 2,289.00 1,944.00 1,944.00 INJECTION 450 MG

SOLUTION FOR SANDIMMUN CICLOSPORINE 10 AMPULE 1 ML 327.80 327.80 INFUSION AT 50 MG

SOLUTION FOR SANDIMMUN CICLOSPORINE 10 AMPULE 5 ML 1,820.40 1,820.40 INFUSION AT 50 MG

ORAL SOLUTION 100 SANDIMMUN CICLOSPORINE 1 BOTTLE 10 ML 550.40 550.40 MG

ORAL SOLUTION 100 NEORAL CICLOSPORINE 1 BOTTLE 20 ML 931.30 931.30 MG

ORAL SOLUTION 100 EQUORAL CICLOSPORINE 1 BOTTLE 50 ML 1,736.00 1,736.00 1,452.00 1,452.00 MG

ORAL SOLUTION 100 NEORAL CICLOSPORINE 1 BOTTLE 50 ML 1,736.00 1,736.00 1,452.00 1,452.00 MG

ORAL SOLUTION 100 SANDIMMUN CICLOSPORINE 1 BOTTLE 50 ML 1,755.00 1,736.00 1,472.00 1,452.00 MG

1 BOX 30 EQUORAL CICLOSPORINE CAPSULES 25 MG 338.00 338.00 224.00 224.00 CAPSULE

1 BOX 30 EQUORAL CICLOSPORINE CAPSULES 50 MG 699.00 699.00 463.00 463.00 CAPSULE

1 BOX 30 EQUORAL CICLOSPORINE CAPSULES 100 MG 1,110.00 1,110.00 810.00 810.00 CAPSULE

1 BOX 50 IMUSPORIN CICLOSPORINE CAPSULES 25 MG 544.00 544.00 360.00 360.00 CAPSULE MOLLE

1 BOX 50 IMUSPORIN CICLOSPORINE CAPSULES 50 MG 1,063.00 1,063.00 762.00 762.00 CAPSULE MOLLE

1 BOX 50 IMUSPORIN CICLOSPORINE CAPSULES 100 MG 1,691.00 1,691.00 1,406.00 1,406.00 CAPSULE MOLLE

1 BOX 50 EQUORAL CICLOSPORINE CAPSULES 25 MG 544.00 544.00 360.00 360.00 CAPSULE

1 BOX 50 SANDIMMUN CICLOSPORINE CAPSULES 25 MG 565.00 544.00 374.00 360.00 CAPSULE

1 BOX 50 EQUORAL CICLOSPORINE CAPSULES 50 MG 1,063.00 1,063.00 762.00 762.00 CAPSULE

1 BOX 50 SANDIMMUN CICLOSPORINE CAPSULES 50 MG 1,123.00 1,063.00 823.00 762.00 CAPSULE

1 BOX 50 EQUORAL CICLOSPORINE CAPSULES 100 MG 1,638.00 1,638.00 1,351.00 1,351.00 CAPSULE

1 BOX 50 SANDIMMUN CICLOSPORINE CAPSULES 100 MG 1,746.00 1,691.00 1,463.00 1,406.00 CAPSULE

1 BOX 60 NEORAL CICLOSPORINE CAPSULES 25 MG 653.00 653.00 432.00 432.00 CAPSULE

1 BOX 60 NEORAL CICLOSPORINE CAPSULES 50 MG 1,213.00 1,213.00 915.00 915.00 CAPSULE

1 BOX 60 NEORAL CICLOSPORINE CAPSULES 100 MG 1,966.00 1,966.00 1,688.00 1,688.00 CAPSULE

SOLUTION FOR CEPLATIN CISPLATINE 1 BOX 1 BOTTLE 37.80 37.80 23.60 23.60 INFUSION AT 10 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 43.00 43.00 26.90 26.90 EBEWE INFUSION AT 10 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 45.00 45.00 28.10 28.10 COOPER INFUSION AT 10 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 51.40 51.40 32.10 32.10 MYLAN INFUSION AT 10 MG

SOLUTION FOR PLATAMINE CISPLATINE 1 BOX 1 BOTTLE 67.70 51.40 42.30 32.10 INFUSION AT 10 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 80.10 80.10 50.10 50.10 MYLAN INFUSION AT 25 MG

SOLUTION FOR CEPLATIN CISPLATINE 1 BOX 1 BOTTLE 117.90 117.90 73.70 73.70 INFUSION AT 50 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 133.00 133.00 83.10 83.10 EBEWE INFUSION AT 50 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 140.00 140.00 87.50 87.50 COOPER INFUSION AT 50 MG

CISPLATINE SOLUTION FOR CISPLATINE 1 BOX 1 BOTTLE 154.20 154.20 96.40 96.40 MYLAN INFUSION AT 50 MG

SOLUTION FOR PLATAMINE CISPLATINE 1 BOX 1 BOTTLE 197.70 154.20 123.60 96.40 INFUSION AT 50 MG

CYCLOMIDE POWDER FOR CYCLOPHOSPHAMI NOVOPHARMA PARAENTERAL USE 1 BOX 1 BOTTLE 51.00 51.00 31.90 31.90 DE 1000 MG À 1 G

CYCLOPHOSPHAMI ENDOXAN 1 G INJECTABLE IV À 1 G 1 BOX 1 BOTTLE 89.40 51.00 55.90 31.90 DE

CYCLOMIDE POWDER FOR CYCLOPHOSPHAMI NOVOPHARMA PARAENTERAL USE 1 BOX 1 BOTTLE 34.20 34.20 21.40 21.40 DE 500 MG À 500 MG POWDER FOR CYCLOPHOSPHAMI SOLUTION ENDOXAN 500 MG 1 BOX 1 BOTTLE 56.10 34.20 35.10 21.40 DE INJECTABLE IV À 500 MG

Price in Price for Common Public Price Price base for Special or trade Hospital reimburse International Form of drug Presentation in Morocco reimbursement name Morocco ment name (PPM) (PPM) (PHM) (PHM) POWDER FOR CYCLOPHOSPHAMI SOLUTION ENDOXAN 200 MG 1 BOX 10 BOTTLE 184.30 184.30 115.20 115.20 DE INJECTABLE IV À 500 MG

CYCLOPHOSPHAMI COATED TABLETS 50 ENDOXAN 50 MG 2 BOX 50 TABLETS 87.20 87.20 54.50 54.50 DE MG

COATED TABLETS 50 ANDROCUR CYPROTERONE 1 BOX 20 TABLETS 201.00 201.00 125.70 125.70 MG

CYTARABINE SOLUTION FOR CYTARABINE 1 BOTTLE 5 ML 42.00 42.00 26.20 26.20 EBEWE INFUSION AT 100 MG

CYTARABINE SOLUTION FOR CYTARABINE 1 BOTTLE 10 ML 195.00 195.00 121.90 121.90 EBEWE INFUSION AT 500 MG

POWDER FOR ARACYTINE CYTARABINE SOLUTION 1 BOTTLE 5 ML 436.00 436.00 290.00 290.00 INJECTION 1 G POWDER FOR 1 BOX 1 AMPULE ARACYTINE CYTARABINE SOLUTION 54.40 54.40 34.00 34.00 INJECTION INJECTION 100 MG POWDER FOR ARACYTINE CYTARABINE SOLUTION 1 BOTTLE 5 ML 232.00 232.00 145.40 145.40 INJECTION 500 MG

POWDER FOR D-BLASTIN DAUNORUBICINE 1 BOX 1 BOTTLE 126.00 126.00 78.70 78.70 INFUSION AT 20 MG

POWDER FOR CERUBIDINE DAUNORUBICINE 1 BOX 10 BOTTLE 1,050.00 1,050.00 772.00 772.00 INFUSION AT 20 MG

CONCENTRATION OF DOCEWIN 20 DOCETAXEL SOLUTION FOR 1 BOTTLE 0,5 ML 800.00 800.00 532.00 532.00 MG/0.5 ML INFUSION AT 20 MG CONCENTRATION OF DOCETAXEL DOCETAXEL SOLUTION FOR 1 BOTTLE 0,5 ML 842.00 842.00 560.00 560.00 COOPER 21 INFUSION AT 20 MG CONCENTRATION OF OKA- DOCETAXEL SOLUTION FOR 1 BOTTLE 0,5 ML 922.00 922.00 640.00 640.00 DOCETAXEL INFUSION AT 20 MG CONCENTRATION OF LEXUS DOCETAXEL SOLUTION FOR 1 BOTTLE 0,5 ML 1,348.00 1,348.00 1,079.00 1,079.00 INFUSION AT 20 MG CONCENTRATION OF TAXOTERE 20 DOCETAXEL SOLUTION FOR 1 BOTTLE 0,5 ML 1,348.00 1,348.00 1,079.00 1,079.00 MG/0.5 ML INFUSION AT 20 MG DOCETAXEL CONCENTRATION OF HOSPIRA 11 DOCETAXEL SOLUTION FOR 1 BOTTLE 2 ML 804.00 804.00 531.80 531.80 MG/ML INFUSION AT 20 MG CONCENTRATION OF DOCEWIN 80 DOCETAXEL SOLUTION FOR 1 BOTTLE 2 ML 2,467.00 2,467.00 2,128.00 2,128.00 MG/2 ML INFUSION AT 80 MG CONCENTRATION OF DOCETAXEL DOCETAXEL SOLUTION FOR 1 BOTTLE 2 ML 2,575.00 2,575.00 2,239.00 2,239.00 COOPER 80 MG INFUSION AT 80 MG CONCENTRATION OF OKA- DOCETAXEL SOLUTION FOR 1 BOTTLE 2 ML 2,877.00 2,877.00 2,550.00 2,550.00 DOCETAXEL INFUSION AT 80 MG CONCENTRATION OF LEXUS DOCETAXEL SOLUTION FOR 1 BOTTLE 2 ML 3,177.00 3,177.00 2,858.00 2,858.00 INFUSION AT 80 MG CONCENTRATION OF TAXOTERE 80 DOCETAXEL SOLUTION FOR 1 BOTTLE 2 ML 3,177.00 3,177.00 2,858.00 2,858.00 MG/2 ML INFUSION AT 80 MG

CONCENTRATION OF DOCETAXEL DOCETAXEL SOLUTION FOR 1 BOTTLE 8 ML 2,572.00 2,572.00 1,701.40 1,701.40 HOSPIRA 10 INFUSION AT 80 MG

DOXORUBICINE SOLUTION FOR DOXORUBICINE 1 BOX 1 BOTTLE 74.00 74.00 46.20 46.20 EBEWE INFUSION AT 10 MG

SOLUTION FOR D-RUBICIN-10 DOXORUBICINE 1 BOX 1 BOTTLE 95.30 95.30 59.60 59.60 INFUSION AT 10 MG

LYOPHILASATE FOR ADRIBLASTINE DOXORUBICINE 1 BOX 1 BOTTLE 109.50 95.30 68.40 59.60 INFUSION 10 MG

DOXORUBICINE SOLUTION FOR DOXORUBICINE 1 BOX 1 BOTTLE 313.00 313.00 208.00 208.00 EBEWE INFUSION AT 50 MG

SOLUTION FOR D-RUBICIN-50 DOXORUBICINE 1 BOX 1 BOTTLE 412.00 412.00 273.00 273.00 INFUSION AT 50 MG

ADRIBLASTINE LYOPHILASATE FOR DOXORUBICINE 1 BOX 1 BOTTLE 454.00 412.00 302.00 273.00 RD INFUSION 50 MG

DOXORUBICINE LYOPHILASATE FOR DOXORUBICINE 1 BOTTLE 10 ML 93.00 93.00 58.10 58.10 COOPER INFUSION 50 MG

DOXORUBICINE LYOPHILASATE FOR DOXORUBICINE 1 BOTTLE 50 ML 429.00 429.00 285.00 285.00 COOPER INFUSION 10 MG

LYOPHILASATE FOR OKARUBICIN DOXORUBICINE INFUSION INJECTION 1 BOX 1 BOTTLE 90.00 90.00 56.20 56.20 10 MG LYOPHILASATE FOR OKARUBICIN DOXORUBICINE INFUSION INJECTION 1 BOX 1 BOTTLE 407.00 407.00 270.00 270.00 50 MG SOLUTION FOR EPIRUBICINE EPIRUBICINE INFUSION AT 10 / 5 1 BOX 1 BOTTLE 74.40 74.40 46.50 46.50 MYLAN 2 MG/ML MG/ML POWDER FOR FARMORUBICINE EPIRUBICINE INFUSION AT 10 / 5 1 BOX 1 BOTTLE 110.10 74.40 68.80 46.50 MG/ML SOLUTION FOR EPIRUBICINE EPIRUBICINE INFUSION AT 50 / 25 1 BOX 1 BOTTLE 325.00 325.00 216.00 216.00 MYLAN 2 MG/ML MG/ML POWDER FOR FARMORUBICINE EPIRUBICINE INFUSION AT 50 / 25 1 BOX 1 BOTTLE 495.00 325.00 329.00 216.00 MG/ML

1 BOX 100 ESTRACYT ESTRAMUSTINE CAPSULE 140 MG 1,471.00 1,471.00 1,206.00 1,206.00 CAPSULE

CONCENTRATION OF ETOPOSIDE ETOPOSIDE SOLUTION FOR 1 BOX 1 BOTTLE 118.00 118.00 73.70 73.70 COOPER INFUSION AT 100 MG CONCENTRATION OF OKA-ETOPOSIDE ETOPOSIDE SOLUTION FOR 1 BOX 1 BOTTLE 126.00 126.00 78.70 78.70 INFUSION AT 100 MG

POWDER FOR ETOPOPHOS ETOPOSIDE 1 BOX 1 BOTTLE 494.10 126.00 326.80 78.70 INFUSION AT 100 MG

CONCENTRATION OF ETOPOSIDE ETOPOSIDE SOLUTION FOR 1 BOX 5 BOTTLE 529.00 529.00 352.00 352.00 COOPER INFUSION AT 100 MG CONCENTRATION OF VEPESIDE ETOPOSIDE SOLUTION FOR 1 BOX 5 BOTTLE 874.70 352.00 INFUSION AT 100 MG

CONCENTRATION OF ETOPOSIDE ETOPOSIDE SOLUTION FOR 1 BOTTLE 5 ML 118.00 118.00 73.70 73.70 EBEWE INFUSION AT 20 MG CONCENTRATION OF ETOPOSIDE ETOPOSIDE SOLUTION FOR 10 BOTTLE 5 ML 1,013.00 1,013.00 734.00 734.00 MYLAN INFUSION AT 100 MG CONCENTRATION OF ETOPOSIDE ETOPOSIDE SOLUTION FOR 10 BOTTLE 10 ML 1,465.00 1,465.00 1,200.00 1,200.00 MYLAN INFUSION AT 20 MG CONCENTRATION OF ETOPOSIDE ETOPOSIDE SOLUTION FOR 1 BOTTLE 2,5 ML 62.00 62.00 38.70 38.70 EBEWE INFUSION AT 20 MG

ETOPOSIDE ETOPOSIDE CAPSULE À 50 MG 1 BOX 4 CAPSULE 190.00 190.00 COOPER

ETOPOSIDE 1 BOX 10 ETOPOSIDE CAPSULE À 50 MG 425.00 425.00 COOPER CAPSULE

COATED TABLETS 25 AROMASINE EXEMESTANE 1 BOX 30 TABLETS 969.00 969.00 689.00 689.00 MG

FILM-COATED FLUDARA FLUDARABINE 1 BOX 15 TABLETS 3,606.00 3,606.00 3,301.00 3,301.00 TABLETS 10 MG

FILM-COATED FLUDARA FLUDARABINE 1 BOX 20 TABLETS 4,940.00 4,940.00 4,673.00 4,673.00 TABLETS 10 MG

FLUOROURACIL SOLUTION FOR FLUOROURACIL 1 BOX 1 BOTTLE 13.90 13.90 9.20 9.20 E MYLAN INFUSION AT 250 MG

FLUOROURACIL SOLUTION FOR FLUOROURACIL INJECTION 69.00 69.00 43.10 43.10 EBEWE INFUSION AT 250 MG

FLUORO SOLUTION FOR FLUOROURACIL 1 BOX 12 VIALS 257.00 257.00 161.00 161.00 URACILE ICN INFUSION AT 250 MG

PHARMAURACIL SOLUTION FLUOROURACIL 1 BOX 1 BOTTLE 16.60 16.60 10.40 10.40 250MG/10ML INJECTION 250 MG

SOLUTION PHARMAURACIL FLUOROURACIL 1 BOTTLE 20 ML 25.00 25.00 16.50 16.50 INJECTION 500 MG

COATED TABLETS 1 BOX 30 TABLETS ANDRAXAN FLUTAMIDE 250.00 250.00 156.20 156.20 250 MG ENROBE

EULEXINE FLUTAMIDE TABLETS 250 MG 1 BOX 30 TABLETS 283.00 283.00 188.40 188.40

FLUTAM FLUTAMIDE TABLETS 250 MG 1 BOX 30 TABLETS 283.00 283.00 188.40 188.40

FOLINATE DE SOLUTION LEDERFOLINE 1 BOX 1 AMPULE 17.70 17.70 11.70 11.70 CALCIUM INJECTION 5 MG

FOLINATE DE LEDERFOLINE TABLETS 25 MG 1 BOX 6 TABLETS 104.50 104.50 65.10 65.10 CALCIUM

FOLINATE DE LEDERFOLINE TABLETS 15 MG 1 BOX 10 TABLETS 109.20 109.20 68.00 68.00 CALCIUM

FOLINATE DE LEDERFOLINE TABLETS 5 MG 1 BOX 20 TABLETS 97.60 97.60 60.80 60.80 CALCIUM

FOLINATE DE PREPARATION ELVORINE 1 BOX 1 BOTTLE 52.00 52.00 32.40 32.40 CALCIUM INJECTION 25 MG

FOLINATE DE PREPARATION ELVORINE 1 BOX 1 BOTTLE 100.00 100.00 62.30 62.30 CALCIUM INJECTION 50 MG

FOLINATE DE POWDER FOR CALCIUM FOLINATE DE SOLUTION 1 BOX 1 BOTTLE 115.00 115.00 71.60 71.60 AGUETTANT 100 CALCIUM INJECTION 100 MG MG POWDER FOR FOLINATE DE ELVORINE SOLUTION 1 BOX 1 BOTTLE 195.00 115.00 121.50 71.60 CALCIUM INJECTION 100 MG

FOLINATE DE PREPARATION ELVORINE 1 BOX 1 BOTTLE 338.00 338.00 224.00 224.00 CALCIUM INJECTION 175 MG

FOLINATE DE CALCIUM FOLINATE DE PREPARATION 1 BOX 10 BOTTLE 677.00 677.00 448.00 448.00 AGUETTANT 50 CALCIUM INJECTION 50 MG MG

FOLINATE DE LEDERFOLINE TABLETS 25 MG 1 BOX 6 TABLETS 104.50 104.50 65.10 65.10 CALCIUM

FOLINATE DE LEDERFOLINE TABLETS 15 MG 1 BOX 10 TABLETS 109.20 109.20 68.00 68.00 CALCIUM

FOLINATE DE LEDERFOLINE TABLETS 5 MG 1 BOX 20 TABLETS 97.60 97.60 60.80 60.80 CALCIUM

POWDER FOR MODIFIEE CITAFINE 1G SOLUTION FOR 1 BOTTLE 50 ML 971.00 971.00 691.00 691.00 GEMCITABINE INFUSION AT 1 G POWDER FOR GEMCITABINE GEMCITABINE SOLUTION FOR 1 BOTTLE 50 ML 971.00 971.00 691.00 691.00 HOSPIRA 1 G INFUSION AT 1 G POWDER FOR ONGECIN GEMCITABINE SOLUTION FOR 1 BOTTLE 50 ML 971.00 971.00 691.00 691.00 INFUSION AT 1 G

POWDER FOR GEMZAR GEMCITABINE 1 BOTTLE 50 ML 1,200.00 971.00 927.00 691.00 INFUSION AT 1 G

POWDER FOR GEMCITABINE GEMCITABINE SOLUTION FOR 1 BOTTLE 10 ML 257.00 257.00 161.20 161.20 HOSPIRA 200 MG INFUSION AT 200 MG POWDER FOR ONGECIN GEMCITABINE SOLUTION FOR 1 BOTTLE 10 ML 257.00 257.00 161.20 161.20 INFUSION AT 200 MG POWDER FOR GEMZAR GEMCITABINE SOLUTION FOR 1 BOTTLE 10 ML 369.00 257.00 245.00 161.20 INFUSION AT 200 MG

ZOLADEX 10.8 IMPLANT INJECTION GOSERELINE 1 KIT 1 IMPLANT 3,340.00 3,340.00 3,026.00 3,026.00 MG 10.8 MG

IMPLANT INJECTION ZOLADEX 3.6 MG GOSERELINE 1 BOX 1 SYRINGE 1,346.00 1,346.00 1,077.00 1,077.00 3.6 MG

HYDROXYCARBAM 1 BOX 20 HYDREA CAPSULE 500 MG 66.20 66.20 41.40 41.40 IDE CAPSULE

POWDER FOR ZAVEDOS IDARUBICINE SOLUTION FOR 1 BOTTLE 1 ML 994.00 994.00 715.00 715.00 INFUSION AT 5 MG POWDER FOR ZAVEDOS IDARUBICINE SOLUTION FOR 1 BOTTLE 1 ML 1,320.00 1,320.00 1,050.00 1,050.00 INFUSION AT 10 MG

POWDER FOR HOLOXAN IFOSFAMIDE 1 BOX 1 BOTTLE 409.00 409.00 272.00 272.00 INFUSION AT 1 G

POWDER FOR HOLOXAN IFOSFAMIDE 1 BOX 1 BOTTLE 826.00 826.00 549.00 549.00 INFUSION AT 2 G

POWDER FOR HOLOXAN IFOSFAMIDE 1 BOX 1 BOTTLE 258.00 258.00 161.20 161.20 INFUSION AT 500 MG

FILM-COATED 1 BOX 60 TABLETS GLIVEC IMATINIB 11,940.00 3,800.00 11,714.00 3,500.00 TABLETS 100 MG PELLICULE

1 BOX 120 IMATEC IMATINIB CAPSULE 100 MG 3,800.00 3,800.00 3,500.00 3,500.00 CAPSULE

IMATINIB 1 BOX 120 IMATINIB CAPSULE 100 MG 3,800.00 3,800.00 3,500.00 3,500.00 COOPER CAPSULE

1 BOX 120 GLIVEC IMATINIB CAPSULE 100 MG 20,399.00 3,800.00 20,007.00 3,500.00 CAPSULE

REMICADE INFLIXIMAB 1 BOTTLE 20 ML 6,340.00 6,340.00 6,067.00 6,067.00

CONCENTRATION OF TECAN IRINOTECAN SOLUTION FOR 1 BOX 1 BOTTLE 1,313.00 1,313.00 1,043.00 1,043.00 INFUSION AT 100 MG CONCENTRATION OF IRINOTECAN IRINOTECAN SOLUTION FOR 1 BOTTLE 2 ML 506.00 506.00 336.00 336.00 COOPER INFUSION AT 40 MG CONCENTRATION OF CAMPTO IRINOTECAN SOLUTION FOR 1 BOTTLE 2 ML 533.00 533.00 354.00 354.00 INFUSION AT 40 MG CONCENTRATION OF IRINOCYT 40 IRINOTECAN SOLUTION FOR 1 BOTTLE 2 ML 533.00 533.00 354.00 354.00 MG/2ML INFUSION AT 40 MG CONCENTRATION OF IRINOTECAN IRINOTECAN SOLUTION FOR 1 BOTTLE 5 ML 1,096.00 1,096.00 819.00 819.00 COOPER INFUSION AT 100 MG CONCENTRATION OF CAMPTO IRINOTECAN SOLUTION FOR 1 BOTTLE 5 ML 1,313.00 1,313.00 1,043.00 1,043.00 INFUSION AT 100 MG CONCENTRATION OF IRINOCYT 100 IRINOTECAN SOLUTION FOR 1 BOTTLE 5 ML 1,313.00 1,313.00 1,043.00 1,043.00 MG/5ML INFUSION AT 100 MG

TYKERB LAPATINIB TABLETS 250 MG 1 BOX 70 TABLETS 11,182.00 11,182.00 10,971.00 10,971.00

FILM-COATED ARAVA LEFLUNOMIDE 1 BOX 3 TABLETS 365.00 365.00 242.00 242.00 TABLETS 100 MG

FILM-COATED ARAVA LEFLUNOMIDE 1 BOX 30 TABLETS 556.00 556.00 368.00 368.00 TABLETS 10 MG

FILM-COATED ARAVA LEFLUNOMIDE 1 BOX 30 TABLETS 721.00 721.00 477.00 477.00 TABLETS 20 MG

FILM-COATED 1 BOX 30 TABLETS FEMARA LETROZOLE 1,021.00 713.00 742.00 474.00 TABLETS 2.5 MG PELLICULE

1 BOX 30 TABLETS LETROZOLE GT LETROZOLE TABLETS 2.5 MG 713.00 713.00 474.00 474.00 SECABLE

1 BOX 60 TABLETS LETROZOL GT LETROZOLE TABLETS 2.5 MG 1,110.00 1,110.00 834.00 834.00 SECABLE

FILM-COATED 1 BOX 50 TABLETS ALKERAN 2 MG MELPHALAN 100.40 100.40 62.70 62.70 TABLETS 2 MG PELLICULE

PURINETHOL MERCAPTOPURINE TABLETS 50 MG 1 BOX 25 TABLETS 47.50 47.50 29.70 29.70

1 BOX 100 PENTASA MESALAZINE TABLETS 500 MG 587.00 587.00 389.00 389.00 TABLETS

RECTAL SUSPENSION PENTASA MESALAZINE 5 BOTTLE 100 ML 256.00 256.00 159.80 159.80 1 G

1 BOX 15 PENTASA MESALAZINE SUPPOSITORY 1 G 337.00 337.00 223.00 223.00 SUPPOSITORY

SOLUTION FOR UROMITEXAN MESNA 15 AMPULE 4 ML 339.00 339.00 224.00 224.00 INFUSION AT 400 MG

POWDER FOR LEDERTREXATE METHOTREXATE SOLUTION 1 BOX 1 BOTTLE 492.50 492.50 325.60 325.60 INJECTION 1 G METHOTREXATE MYLAN METHOTREXATE INJECTION 5 G 10 BOTTLE 50 ML 11,067.00 11,067.00 10,858.00 10,858.00 100MG/ML

METHOTREXATE METHOTREXATE INJECTION 5 G 1 BOTTLE 200 ML 1,392.00 1,392.00 1,124.00 1,124.00 MYLAN

LEDERTREXATE METHOTREXATE INJECTION 5 G 1 BOTTLE 200 ML 2,491.30 1,392.00 1,648.00 1,124.00

METHOTREXATE METHOTREXATE INJECTION 25 MG 1 BOTTLE 1 ML 36.30 36.30 22.70 22.70 BELLON

METHOTREXATE METHOTREXATE INJECTION 25 MG 1 BOTTLE 1 ML 47.10 47.10 29.40 29.40 BIODIM

METHOTREXATE METHOTREXATE INJECTION 5 MG 1 BOTTLE 2 ML 21.20 21.20 13.20 13.20 BELLON

METHOTREXATE METHOTREXATE INJECTION 5 MG 1 BOTTLE 2 ML 30.70 30.70 19.20 19.20 BIODIM

LEDERTREXATE METHOTREXATE INJECTION 50 MG 1 BOTTLE 2 ML 81.90 81.90 51.20 51.20 50 MG

METHOTREXATE METHOTREXATE INJECTION 5 MG 10 BOTTLE 2 ML 178.00 178.00 111.20 111.20 MYLAN

METHOTREXATE MYLAN 50 MG/2 METHOTREXATE INJECTION 50 MG 10 BOTTLE 2 ML 486.00 486.00 323.00 323.00 ML

METHOTREXATE METHOTREXATE INJECTION 500 MG 10 BOTTLE 20 ML 1,340.00 1,340.00 1,071.00 1,071.00 MYLAN

METHOTREXATE METHOTREXATE INJECTION 500 MG 10 BOTTLE 20 ML 2,465.60 1,340.00 1,631.00 1,071.00 BELLON (H)

CONCENTRATION OF MITOXANTRONE MITOXANTRONE SOLUTION FOR 1 BOX 1 BOTTLE 1,199.00 1,199.00 926.00 926.00 EBEWE INFUSION AT 10 MG

CONCENTRATION OF MITOXANTRONE MITOXANTRONE SOLUTION FOR 1 BOX 1 BOTTLE 2,099.00 2,099.00 1,852.00 1,852.00 EBEWE INFUSION AT 20 MG

SOLUTION FOR NOVANTRONE MITOXANTRONE 1 AMPULE 5 ML 2,247.30 2,247.30 1,486.60 1,486.60 INFUSION AT 10 MG

SOLUTION FOR NOVANTRONE MITOXANTRONE 1 AMPULE 10 ML 4,167.40 4,167.40 2,756.70 2,756.70 INFUSION AT 20 MG

SOLUTION FOR NOVANTRONE MITOXANTRONE 1 AMPULE 12,5 ML 4,948.70 4,948.70 3,273.60 3,273.60 INFUSION AT 25 MG

MYCOPHENOLATE FILM-COATED CELLCEPT 1 BOX 50 TABLETS 1,203.00 1,203.00 905.00 905.00 MOFETIL TABLETS 500 MG

MYCOPHENOLATE 1 BOX 100 CELLCEPT CAPSULE 250 MG 1,203.00 1,203.00 905.00 905.00 MOFETIL CAPSULE

POWDER FOR ELOXATINE 5 1 BOX 1 BOTTLE OXALIPLATINE SOLUTION FOR 1,203.00 1,203.00 929.00 929.00 MG/ML 10 ML INFUSION AT 50 MG POWDER FOR ELOXATINE 5 1 BOX 1 BOTTLE OXALIPLATINE SOLUTION FOR 2,206.00 2,206.00 1,859.00 1,859.00 MG/ML 20 ML INFUSION AT 100 MG CONCENTRATION OF ELOXATINE 5 1 BOX 1 BOTTLE OXALIPLATINE SOLUTION FOR 2,882.00 2,882.00 2,555.00 2,555.00 MG/ML 40 ML INFUSION AT 200 MG

POWDER FOR OLIPLAT OXALIPLATINE 1 BOX 1 BOTTLE 1,203.00 1,203.00 929.00 929.00 INFUSION AT 50 MG

POWDER FOR OLIPLAT OXALIPLATINE SOLUTION FOR 1 BOX 1 BOTTLE 2,206.00 2,206.00 1,859.00 1,859.00 INFUSION AT 100 MG CONCENTRATION OF OXALISIN 5 OXALIPLATINE SOLUTION FOR 1 BOTTLE 10 ML 1,089.00 1,089.00 812.00 812.00 MG/ML INFUSION AT 50 MG CONCENTRATION OF XYLATIN 50 OXALIPLATINE SOLUTION FOR 1 BOTTLE 10 ML 1,089.00 1,089.00 812.00 812.00 INFUSION AT 100 MG CONCENTRATION OF OXALISIN 5 OXALIPLATINE SOLUTION FOR 1 BOTTLE 20 ML 1,864.00 1,864.00 1,610.00 1,610.00 MG/ML INFUSION AT 50 MG POWDER FOR XYLATIN 100 OXALIPLATINE SOLUTION FOR 1 BOTTLE 20 ML 1,869.00 1,869.00 1,615.00 1,615.00 INFUSION AT 100 MG

OXAPLATINE POWDER FOR OXALIPLATINE 1 BOTTLE 30 ML 1,203.00 1,203.00 929.00 929.00 MYLAN 5 MG/ML INFUSION AT 50 MG

OXALIPLATINE POWDER FOR OXALIPLATINE 1 BOTTLE 36 ML 1,049.00 1,049.00 771.00 771.00 WIN 5 MG/ML INFUSION AT 50 MG

ELOXATINE 5 POWDER FOR OXALIPLATINE 1 BOTTLE 36 ML 1,203.00 1,049.00 929.00 771.00 MG/ML INFUSION AT 50 MG

OXALIPLATINE POWDER FOR OXALIPLATINE 1 BOTTLE 50 ML 1,468.00 1,468.00 1,203.00 1,203.00 WIN 5 MG/ML INFUSION AT 100 MG

ELOXATINE 5 POWDER FOR OXALIPLATINE 1 BOTTLE 50 ML 2,206.00 2,206.00 1,859.00 1,859.00 MG/ML INFUSION AT 100 MG

OXAPLATINE POWDER FOR OXALIPLATINE 1 BOTTLE 50 ML 2,206.00 2,206.00 1,859.00 1,859.00 MYLAN 5 MG/ML INFUSION AT 100 MG

SYNTOCINON OXYTOCINE INJECTION 5 UI 3 AMPULE 1 ML 17.20 17.20 10.70 10.70

CONCENTRATION OF ACUPAXIL-30 PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 430.00 430.00 285.00 285.00 INFUSION AT 30 MG PACLITAXEL CONCENTRATION OF MYLAN PHARMA PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 430.00 430.00 285.00 285.00 30 MG/5ML INFUSION AT 30 MG PACLITAXEL CONCENTRATION OF PHARMACHEMIE PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 430.00 430.00 285.00 285.00 6MG/ML INFUSION AT 30 MG CONCENTRATION OF PACLITAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 452.00 452.00 300.00 300.00 COOPER INFUSION AT 30 MG CONCENTRATION OF OKA- PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 527.00 527.00 350.00 350.00 PACLITAXEL INFUSION AT 30 MG CONCENTRATION OF EBETAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 590.00 590.00 392.00 392.00 INFUSION AT 30 MG CONCENTRATION OF ANZATAX PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 619.00 619.00 411.00 411.00 INFUSION AT 30 MG CONCENTRATION OF PAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 619.00 619.00 411.00 411.00 INFUSION AT 30 MG CONCENTRATION OF TAXOL PACLITAXEL SOLUTION FOR 1 BOTTLE 5 ML 619.00 619.00 411.00 411.00 INFUSION AT 30 MG CONCENTRATION OF OKA- PACLITAXEL SOLUTION FOR 1 BOTTLE 20 ML 1,271.00 1,271.00 1,000.00 1,000.00 PACLITAXEL INFUSION AT 100 MG PACLITAXEL CONCENTRATION OF PHARMACHEMIE PACLITAXEL SOLUTION FOR 1 BOTTLE 25 ML 1,341.00 1,341.00 1,071.00 1,071.00 6MG/ML INFUSION AT 150 MG CONCENTRATION OF EBETAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 25 ML 2,317.00 2,317.00 1,973.00 1,973.00 INFUSION AT 150 MG CONCENTRATION OF ANZATAX PACLITAXEL SOLUTION FOR 1 BOTTLE 25 ML 2,476.00 2,476.00 2,137.00 2,137.00 INFUSION AT 150 MG PACLITAXEL CONCENTRATION OF MYLAN PHARMA PACLITAXEL SOLUTION FOR 1 BOTTLE 50 ML 1,574.00 1,574.00 1,312.00 1,312.00 300 MG/50 ML INFUSION AT 300 MG PACLITAXEL CONCENTRATION OF PHARMACHEMIE PACLITAXEL SOLUTION FOR 1 BOTTLE 50 ML 2,069.00 2,069.00 1,821.00 1,821.00 6MG/ML INFUSION AT 300 MG CONCENTRATION OF EBETAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 50 ML 4,043.00 4,043.00 3,750.00 3,750.00 INFUSION AT 300 MG PACLITAXEL CONCENTRATION OF MYLAN PHARMA PACLITAXEL SOLUTION FOR 1 BOTTLE 16,7 ML 823.00 823.00 547.00 547.00 100 MG/16.7 ML INFUSION AT 100 MG PACLITAXEL CONCENTRATION OF PHARMACHEMIE PACLITAXEL SOLUTION FOR 1 BOTTLE 16,7 ML 823.00 823.00 547.00 547.00 6MG/ML INFUSION AT 100 MG CONCENTRATION OF PACLITAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 16,7 ML 1,115.00 1,115.00 839.00 839.00 COOPER INFUSION AT 100 MG CONCENTRATION OF EBETAXEL PACLITAXEL SOLUTION FOR 1 BOTTLE 16,7 ML 1,563.00 1,563.00 1,300.00 1,300.00 INFUSION AT 100 MG

POWDER FOR ALIMTA PEMETREXED SOLUTION FOR 1 BOX 1 BOTTLE 2,974.00 2,650.00 INFUSION AT 100 MG POWDER FOR ALIMTA PEMETREXED SOLUTION FOR 1 BOX 1 BOTTLE 11,999.00 11,771.00 INFUSION AT 500 MG

POWDER FOR TOMUDEX RALTITREXED 1 BOX 1 BOTTLE 1,715.00 1,456.00 INFUSION AT 2 MG

CONCENTRATION OF MABTHERA RITUXIMAB SOLUTION FOR 2 BOTTLE 10 ML 5,842.00 5,842.00 5,602.00 5,602.00 INFUSION AT 100 MG CONCENTRATION OF MABTHERA RITUXIMAB SOLUTION FOR 1 BOTTLE 50 ML 13,737.00 13,737.00 13,475.00 13,475.00 INFUSION AT 500 MG

FILM-COATED NEXAVAR SORAFENIB 1 BOX 60 TABLETS 21,152.00 21,152.00 20,745.00 20,745.00 TABLETS 200 MG

SALAZOPYRIN SULFASALAZINE 141.70 141.70 88.30 88.30

1 BOX 100 PROGRAF TACROLIMUS CAPSULE 1 MG 1,980.00 1,980.00 1,703.00 1,703.00 CAPSULE

TAFEN TAMOXIFENE TABLETS 10 MG 1 BOX 20 TABLETS 50.00 50.00

TAMOXIFENE TAMOXIFENE TABLETS 10 MG 1 BOX 30 TABLETS 78.60 78.60 49.10 49.10 MYLAN

FILM-COATED NOLVADEX TAMOXIFENE 1 BOX 30 TABLETS 132.50 78.60 87.60 49.10 TABLETS 10 MG

COATED TABLETS 20 NOLVADEX TAMOXIFENE 1 BOX 30 TABLETS 124.30 124.30 77.70 77.70 MG

TAFEN TAMOXIFENE TABLETS 20 MG 1 BOX 30 TABLETS 124.30 124.30 77.70 77.70

TAMOXIFENE GT TAMOXIFENE TABLETS 20 MG 1 BOX 30 TABLETS 124.30 124.30 77.70 77.70 20 MG

TAMOXIFENE TAMOXIFENE TABLETS 20 MG 1 BOX 30 TABLETS 124.30 124.30 77.70 77.70 MYLAN

TEGAFUR / CAPSULE 100 / 224 MG 1 BOX 21 UFT 1,831.00 1,831.00 1,576.00 1,576.00 URACILE / MG CAPSULE

TEGAFUR / CAPSULE 100 / 224 MG 1 BOX 28 UFT 2,442.00 2,442.00 2,102.00 2,102.00 URACILE / MG CAPSULE

TEGAFUR / CAPSULE 100 / 224 MG 1 BOX 35 UFT 2,952.00 2,952.00 2,627.00 2,627.00 URACILE / MG CAPSULE

TEGAFUR / CAPSULE 100 / 224 MG 1 BOX 42 UFT 3,463.00 3,463.00 3,153.00 3,153.00 URACILE / MG CAPSULE

1 BOTTLE 5 TEMODAL TEMOZOLOMIDE CAPSULE 5 MG 219.00 219.00 137.00 137.00 CAPSULE

1 BOTTLE 5 TEMODAL TEMOZOLOMIDE CAPSULE 20 MG 840.00 840.00 558.00 558.00 CAPSULE

1 BOTTLE 5 TEMODAL TEMOZOLOMIDE CAPSULE 100 MG 3,156.00 3,156.00 2,837.00 2,837.00 CAPSULE

1 BOTTLE 5 TEMODAL TEMOZOLOMIDE CAPSULE 250 MG 6,392.00 6,392.00 6,168.00 6,168.00 CAPSULE

POWDER FOR THIOTEPA THIOTEPA PARAENTERAL USE 1 BOX 1 BOTTLE 191.90 191.90 126.90 126.90 À 15 MG POWDER FOR HERCEPTIN TRASTUZUMAB PARAENTERAL USE 1 BOX 1 BOTTLE 6,890.00 6,890.00 6,681.00 6,681.00 À 150 MG POWDER FOR 1 BOX 1 BOTTLE + DECAPEPTYL LP TRIPTORELINE SUSPENSION 1,456.00 1,456.00 1,190.00 1,190.00 AMPULE INJECTION 3.75 MG POWDER FOR 1 BOX 1 BOTTLE + DECAPEPTYL LP TRIPTORELINE SOLUTION 3,546.00 3,546.00 3,239.00 3,239.00 AMPULE INJECTION 11.25 MG POWDER FOR DECAPEPTYL TRIPTORELINE SOLUTION 1 BOX 7 KIT 467.00 467.00 310.00 310.00 INJECTION 0.1 MG POWDER FOR OKA-VINBLASTINVINBLASTINE SOLUTION 1 BOTTLE 10 ML 124.00 124.00 77.50 77.50 INJECTION 10 MG

PHARMACRISTIN SOLUTION VINCRISTINE 1 BOX 1 BOTTLE 55.90 55.90 34.90 34.90 E 1 MG/ML INJECTION 1 MG

VINCRISTINE SOLUTION VINCRISTINE 1 BOX 1 BOTTLE 65.00 65.00 40.60 40.60 COOPER INJECTION 1 MG

OKA- SOLUTION VINCRISTINE 1 BOX 1 BOTTLE 68.00 68.00 42.50 42.50 VINCRISTINE INJECTION 1 MG

VINCRISTINE SOLUTION VINCRISTINE 1 BOX 5 BOTTLE 306.00 306.00 204.00 204.00 COOPER INJECTION 1 MG

SOLUTION NAVELBINE VINORELBINE 1 BOTTLE 1 ML 246.00 246.00 154.00 154.00 INJECTION 10 MG

SOLUTION NAVELBINE VINORELBINE 10 BOTTLE 1 ML 1,764.00 1,764.00 1,507.00 1,507.00 INJECTION 10 MG

SOLUTION NAVELBINE VINORELBINE 1 BOTTLE 5 ML 1,022.00 1,022.00 743.00 743.00 INJECTION 50 MG

SOLUTION NAVELBINE VINORELBINE 10 BOTTLE 5 ML 7,483.00 7,483.00 7,291.00 7,291.00 INJECTION 50 MG

NAVELBINE VINORELBINE CAPSULES 20 MG 1 BOX 1 CAPSULE 771.00 771.00 512.00 512.00

NAVELBINE VINORELBINE CAPSULES 30 MG 1 BOX 1 CAPSULE 1,028.00 1,028.00 750.00 750.00

SOLUPRED PREDNISOLONE 1 BOX 30 TABLETS 33.30 28.00 20.80 17.50

ISOLONE PREDNISOLONE TABLETS 20 MG 1 BOX 30 TABLETS 57.10 57.10 35.70 35.70

EFFERVESCENT ORAPRED PREDNISOLONE 1 BOX 30 TABLETS 65.00 65.00 40.60 40.60 TABLETS 20 MG

EFFERVESCENT 1 BOX 60 TABLETS ORAPRED 5 MG PREDNISOLONE 38.00 38.00 23.70 23.70 TABLETS 5 MG EFFERVESCENT

CORTANCYL PREDNISONE TABLETS 20 MG 1 BOX 20 TABLETS 45.80 45.80 28.60 28.60

ISONE PREDNISONE TABLETS 20 MG 1 BOX 20 TABLETS 57.10 57.10 35.70 35.70

ISONE PREDNISONE TABLETS 50 MG 1 BOX 20 TABLETS 85.80 85.80 53.60 53.60

ISONE PREDNISONE TABLETS 1 MG 1 BOX 30 TABLETS 12.30 12.30 7.70 7.70

CORTANCYL PREDNISONE TABLETS 1 MG 1 BOX 30 TABLETS 13.40 12.30 8.40 7.70

ISONE PREDNISONE TABLETS 5 MG 1 BOX 30 TABLETS 19.00 19.00 11.90 11.90

CORTANCYL PREDNISONE TABLETS 5 MG 1 BOX 30 TABLETS 22.80 19.00 14.20 11.90

PREDNISONE / ACIDE GASTRO-RESISTANT CEKACORT ASCORBIQUE COATED TABLETS 5 / 1 BOX 30 TABLETS 20.30 20.30 12.70 12.70 (VITAMINE C) / 125 / 125 MG / CHLORURE DE

ORAL SOLUTION 1 EFFIPRED PREDNISOLONE 1 BOTTLE 50 ML 21.60 21.60 13.50 13.50 MG

SOLUPRED PREDNISOLONE SOLUTION 1 MG 1 BOTTLE 50 ML 27.00 21.60 17.90 13.50

EFFERVESCENT COTIPRED PREDNISOLONE 1 BOX 20 TABLETS 48.50 48.50 30.30 30.30 TABLETS 20 MG

PREDNISOLONE EFFERVESCENT 1 BOTTLE 20 PREDNISOLONE 35.50 35.50 22.20 22.20 WIN TABLETS 20 MG TABLETS

HOSTACORTIN H PREDNISOLONE TABLETS 5 MG 1 BOX 20 TABLETS 21.70 21.70 13.60 13.60

SIPROZONE PREDNISOLONE TABLETS 20 MG 1 BOX 20 TABLETS 35.00 35.00 21.90 21.90

EFFERVESCENT ISOLONE PREDNISOLONE 1 BOX 20 TABLETS 40.00 40.00 25.00 25.00 TABLETS 20 MG

EFFERVESCENT PREDNI 20 PREDNISOLONE 1 BOX 20 TABLETS 42.00 42.00 26.20 26.20 TABLETS 20 MG

EFFERVESCENT EFFIPRED PREDNISOLONE 1 BOX 20 TABLETS 58.40 58.40 36.50 36.50 TABLETS 20 MG

EFFERVESCENT SOLUPRED PREDNISOLONE 1 BOX 20 TABLETS 58.40 58.40 36.50 36.50 TABLETS 20 MG

ISOLONE PREDNISOLONE TABLETS 50 MG 1 BOX 20 TABLETS 85.80 85.80 53.60 53.60

EFFERVESCENT ORAPRED 5 MG PREDNISOLONE 1 BOX 30 TABLETS 20.00 20.00 12.50 12.50 TABLETS 5 MG

EFFERVESCENT ISOLONE PREDNISOLONE 1 BOX 30 TABLETS 22.00 22.00 13.70 13.70 TABLETS 5 MG

EFFERVESCENT ISOLONE PREDNISOLONE 1 BOX 30 TABLETS 23.00 23.00 14.40 14.40 TABLETS 5 MG

EFFERVESCENT EFFIPRED PREDNISOLONE 1 BOX 30 TABLETS 28.00 28.00 17.50 17.50 TABLETS 5 MG

6.5 Bibliography

1. book, C.T.W.F. Morocco. [cited 2014 24th July]; Available from: https://www.cia.gov/library/publications/the-world-factbook/fields/2102.html#138. 2. Bank, W. Data: Morocco. 15th April, 2014]; Available from: http://data.worldbank.org/country/morocco. 3. Reports, U.H.D. Morocco. 15th April, 2014]; Available from: http://hdr.undp.org/sites/default/files/Country-Profiles/MAR.pdf. 4. Sante, R.d.M.M.d.l., strategie sectorielle de sante maroc 2012-2016. 2012. 5. Solidarity, E.F.f.D.a. Coutry update-Morocco. 2014 [cited 2014 15th December]; Available from: http://www.europeanforum.net/country/morocco. 6. WHO. THE MOROCCO COUNTRY CASE STUDY: Positive Practice Environments. 18th April, 2014]; Available from: http://www.who.int/workforcealliance/knowledge/PPE_Morocco_CaseStudy.pdf?ua=1. 7. WHO. Country Cooperation Strategy for WHO and Morocco 2008–2013. 16th April, 2014]; Available from: http://www.who.int/countryfocus/cooperation_strategy/ccs_mar_en.pdf. 8. Observatory-WHO, R.H.S., Health System Profile-Morocco. 2006. 9. Ruger, J.P. and D. Kress, Health financing and insurance reform in Morocco. Health Aff (Millwood), 2007. 26(4): p. 1009-16. 10. CNSS, M. Key figures. 30th April, 2014]; Available from: http://www.cnss.ma/fr/content/chiffres- cl%C3%A9s-1. 11. ANAM, Roadmap 2014-18. 2014. 12. experts, D.w., Discussion with experts. 2014. 13. INTERNATIONALHEALTH, H.P.D.T.I.F. REGISTERING NEW DRUGS: THE AFRICAN CONTEXT. 6th April, 2014]; Available from: http://www.policycures.org/downloads/DNDi_Registering_New_Drugs- The_African_Context_20100108.pdf. 14. Dr Javier Guzman, Director of R., Health Policy Division, The George Institute for International Health. REGISTERING NEW DRUGS: THE AFRICAN CONTEXT New tools for new times. 6th April, 2014]; Available from: http://www.conceptfoundation.org/files/meeting/16.%20Guzman%20- %20Registering%20new%20drugs%20the%20African%20context.pdf. 15. Pharmaceutique, A.M.d.l.I. Loi n° 17-04 portant code du médicament et de la pharmacie. [cited 2014 18th July]; Available from: http://www.amip.ma/dynamicdata/Secteur_Codepharmacie.aspx.

6.6 Methodology

6.6.1 Secondary research

In-depth and extensive secondary research was conducted to capture quantitative and qualitative information by a team of experienced consultants with advanced analytical skills and expertise in the pharmaceutical industry. The data was collected from multiple credible and authentic sources within public domain, including but not limited to:

• Websites of Ministry of Health and its affiliates as well as various regulatory and government bodies. • Company websites, annual reports, investor presentations and press releases of various pharmaceutical companies and hospitals. • Reports of various healthcare and pharmaceutical trade associations. • Reports published by various internationally recognized bodies such as World Health Organization (WHO), United Nations (UN), and others. • Reports and articles published by globally accredited institutions such as the World Bank, International Monetary Fund (IMF), Asian Development Bank (ADB), the Organization for Economic Cooperation and Development (OECD), Central Banks of respective countries and many more. • News, press releases and bulletins of domestic as well as foreign newspapers and magazines. • Publications in various scientific, healthcare and other related journals.

6.6.2 Data validation

Both the primary and secondary data was validated by a panel of experts including industry experts, KOLs, thought leaders and members of phamax Dendron Network.

6.7 Disclaimer

All information contained in this publication has been thoroughly researched and compiled from various sources that are believed to be accurate and credible at the time of publishing. However, in view of the natural scope for human and/or mechanical error, either at source or during production, phamax accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions from any part of the publication. All information is provided without warranty, and phamax makes no representation of warranty of any kind as to the accuracy or completeness of any information hereto contained.

The information contained in this report is strictly confidential and has been provided to the client under a non-exclusive and non-transferable license for the client’s direct benefit and use only. The report should not be copied, electronically transmitted, sold or divulged to any other party without the prior written consent of phamax.

6.8 Contact us

All communications pertaining to this report should be addressed to:

SWITZERLAND OFFICE

phamax AG Passage 6, 4104 Oberwil (BL), SWITZERLAND Phone: +41 61821 5687 Fax: +41 61821 5836 E-mail: [email protected]

INDIA OFFICE

phamax Analytic Resources Pvt. Ltd. #19, “KMJ Ascend”, 1st Cross, 17th C Main, 5th Block, Koramangala, Bangalore 560 095, INDIA Phone no: +91 80 6745 1100 Fax no: +91 80 6745 1122 E-mail: [email protected]